



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/12, C07K 14/47, C12N 16/70, 1/21, A61K 38/17, C07K 16/18, C12Q 1/68		A2	(11) International Publication Number: WO 99/15658	
			(43) International Publication Date: 1 April 1999 (01.04.99)	
(21) International Application Number: PCT/US98/19839			Avenue, Berkeley, CA 94702 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). GUEGLER, Karl, J. [CH/US]; 1048 Oakland Avenue, Menlo Park, CA 94025 (US).	
(22) International Filing Date: 22 September 1998 (22.09.98)				
(30) Priority Data: 08/933,750 23 September 1997 (23.09.97) US			(74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/933,750 (CIP) Filed on 23 September 1997 (23.09.97)			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).				
(72) Inventors; and				
(75) Inventors/Applicants (for US only): LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive #12, Mountain View, CA 94040 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). SHAH, Purvi [IN/US]; 1608 Queen Charlotte Drive #5, Sunnyvale, CA 94087 (US). AU-YOUNG, Janice [US/US]; 1419 Kains			Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(54) Title: HUMAN REGULATORY MOLECULES				
(57) Abstract				
<p>The invention provides human regulatory molecules and polynucleotides (collectively designated HRM) which identify and encode them. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention further provides methods for diagnosing, preventing, and treating disorders associated with expression of human regulatory molecules.</p>				

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslavia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	MR	Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	MU	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

HUMAN REGULATORY MOLECULES

5

TECHNICAL FIELD

This invention relates to nucleic acid and amino acid sequences of human regulatory molecules which are important in disease and to the use of these sequences in the diagnosis, prevention, and treatment of diseases associated with cell proliferation.

10

BACKGROUND OF THE INVENTION

Cells grow and differentiate, carry out their structural or metabolic roles, participate in organismal development, and respond to their environment by altering their gene expression. Cellular functions are controlled by the timing and amount of expression attributable to thousands of individual genes. The regulation of expression is metabolically vital in that it 15 conserves energy and prevents the synthesis and accumulation of intermediates such as RNA and incomplete or inactive proteins when the gene product is not needed.

Regulatory protein molecules are absolutely essential in the control of gene expression. These molecules turn individual or groups of genes on and off in response to various inductive mechanisms of the cell or organism; act as transcription factors by 20 determining whether or not transcription is initiated, enhanced, or repressed; and splice transcripts as dictated in a particular cell or tissue. Although regulatory molecules interact with short stretches of DNA scattered throughout the entire genome, most gene expression is regulated near the site at which transcription starts or within the open reading frame of the gene being expressed. The regulated stretches of the DNA can be simple and interact with 25 only a single protein, or they can require several proteins acting as part of a complex to order to regulate gene expression.

The double helix structure and repeated sequences of DNA create external features which can be recognized by the regulatory molecules. These external features are hydrogen bond donor and acceptor groups, hydrophobic patches, major and minor grooves, and regular, 30 repeated stretches of sequence which cause distinct bends in the helix. Such features provide recognition sites for the binding of regulatory proteins. Typically, these recognition sites are less than 20 nucleotides in length although multiple sites may be adjacent to each other and

each may exert control over a single gene. Hundreds of these DNA sequences have been identified, and each is recognized by a different protein or complex of proteins which carry out gene regulation.

The regulatory protein molecules or complexes recognize and bind to specific 5 nucleotide sequences of upstream (5') nontranslated regions, which precede the first translated exon of the open reading frame (ORF); of intron junctions, which occur between the many exons of the OR; and of downstream (3') untranslated regions, which follow the ORF. The regulatory molecule surface features are extensively complementary to the surface features of the double helix. Even though each individual contact between the protein(s) and 10 helix may be relatively weak (hydrogen bonds, ionic bonds, and/or hydrophobic interactions) and the 20 or more contacts occurring between the protein and DNA result in a highly specific and very strong interaction.

Families of regulatory molecules

Many of the regulatory molecules incorporate one of a set of DNA-binding structural 15 motifs, each of which contains either α helices or β sheets and binds to the major groove of DNA. Seven of the structural motifs common to regulatory molecules are helix-turn-helix, homeodomains, zinc finger, steroid receptor, β sheets, leucine zipper, and helix-loop-helix.

The helix-turn-helix motif is constructed from two α helices connected by a short chain of amino acids, which constitutes the "turn". The two helices interact with each other 20 to form a fixed angle. The more carboxy-terminal helix is called the recognition helix because it fits into the major groove of the DNA. The amino acid side chains of the helix recognize the specific DNA sequence to which the protein binds. The remaining structure varies a great deal among the regulatory proteins incorporating this motif. The helix-turn-helix configuration is not stable without the rest of the protein and will not bind to DNA 25 without other peptide regions providing stability. Other peptide regions also interact with the DNA, increasing the number of unique sequences a helix-turn-helix can recognize.

Many sequence-specific DNA binding proteins actually bind as symmetric dimers to 30 DNA sequences that are composed of two very similar half-sites, also arranged symmetrically. This configuration allows each protein monomer to interact in the same way with the DNA recognition site and doubles the number of contacts with the DNA. This doubling of contacts greatly increases the binding affinity while only doubling the free energy of the interaction. Helix-turn-helix motifs always bind to DNA that is in the B-DNA form.

The homeodomain motif is found in a special group of helix-turn-helix proteins that are encoded by homeotic selector genes, so called because the proteins encoded by these genes control developmental switches. For example, mutations in these genes cause one body part to be converted into another in the fruit fly, Drosophila. These genes have been found in 5 every eukaryotic organism studied. The helix-turn-helix region of different homeodomains is always surrounded by the same structure, but not necessarily the same sequence, and the motif is always presented to DNA the same way. This helix-turn-helix configuration is stable by itself and, when isolated, can still bind to DNA. It may be significant that the helices in homeodomains are generally longer than the helices in most HLH regulatory proteins.

10 Portions of the motif which interact most directly with DNA differ among these two families. Detailed examples of DNA-protein binding are described in Pabo, C.O. and R.T. Sauer (1992; Ann. Rev. Biochem. 61:1053-95).

A third motif incorporates zinc molecules into the crucial portion of the protein. These proteins are most often referred to as having zinc fingers, although their structure can 15 be one of several types. Proteins in this family often contain tandem repeats of the 30-residue zinc finger motif, including the sequence patterns Cys-X2 or 4-Cys-X12-His-X3-5-His. Each of these regulatory proteins has an α helix and an antiparallel β sheet. Two histidines in the α helix and 2 cysteines near the turn in the β sheet interact with the zinc ion which holds the α helix and the β sheet together. Contact with the DNA is made by the arginine preceding the α 20 helix, and by the second, third, and sixth residues of the α helix. When this arrangement is repeated as a cluster of several fingers, the α helix of each finger can contact and interact with the major groove of the DNA. By changing the number of zinc fingers, the specificity and strength of the binding interaction can be altered.

The steroid receptors are a family of intracellular proteins that include receptors for 25 steroids, retinoids, vitamin D, thyroid hormones, and other important compounds. The DNA binding domain of these proteins contains about 70 residues, eight of which are conserved cysteines. The steroid receptor motif forms a structure in which two α helices are packed perpendicularly to each other, forming more of a globular shape than a finger. Each helix has a zinc ion which holds a peptide loop against the N-terminal end of the helix. The first helix 30 fits into the major groove of DNA, and side chains make contacts with edges of the DNA base pairs. The steroid receptor proteins, like the helix-turn-helix proteins, form dimers that bind the DNA. The second helix of each monomer contacts the phosphate groups of the

DNA backbone and also provides the dimerization interface. In some cases, multiple choices can exist for heterodimerization which produces another mechanism for fine-tuning the regulation of numerous genes.

Another family of regulatory protein molecules uses a motif consisting of a two-stranded antiparallel β sheet to recognize the major groove of DNA. The exact DNA sequence recognized by the motif depends on the amino acid sequence in the β sheet from which the amino acid side chains extend and contact the DNA. In two prokaryotic examples of the β sheet, the regulatory proteins form tetramers when binding DNA.

The leucine zipper motif commonly forms dimers and has a 30-40 residue motif in which two α helices (one from each monomer) are joined to form a short coiled-coil. The helices are held together by interactions among hydrophobic amino acid side chains (often on heptad-repeated leucines) that extend from one side of each helix. Beyond this, the helices separate, and each basic region contacts the major groove of DNA. Proteins with the leucine zipper motif can also form either homodimers or heterodimers, thus extending the specific combinations available to activate or repress expression.

Yet another important motif is the helix-loop-helix, which consists of a short α helix connected by a loop to a longer α helix. The loop is flexible and allows the two helices to fold back against each other. The α helices bind both to DNA and to the HLH structure of another protein. The second protein can be the same (producing homodimers) or different (producing heterodimers). Some HLH monomers lack sufficient α helix to bind DNA, but they can still form heterodimers which can serve to inactivate specific regulatory proteins.

Hundreds of regulatory proteins have been identified to date, and more are being characterized in a wide variety of organisms. Most regulatory proteins have at least one of the common structural motifs for making contact with DNA, but several important regulatory proteins, such as the p53 tumor suppressor gene, do not share their structure with other known regulatory proteins. Variations on known motifs and new motifs have been and are currently being characterized (Faisst, S. and S. Meyer (1992) Nucl. Acids Res. 20: 3-26).

Although binding of DNA to a regulatory protein is very specific, there is no way to predict the exact DNA sequence to which a particular regulatory protein will bind or the primary structure of a regulatory protein for a specific DNA sequence. Thus, interactions of DNA and regulatory proteins are not limited to the motifs described above. Other domains of the proteins often form crucial contacts with the DNA, and accessory proteins can provide

important interactions which may convert a particular protein complex to an activator, or a repressor, or may prevent binding (Alberts, B. et al. (1994) Molecular Biology of the Cell, Garland Publishing Co, New York NY, pp. 401-74).

Diseases and disorders related to gene regulation

- 5 Many neoplastic growths in humans can be traced to problems of gene regulation. Malignant growth of cells may be the result of excess transcriptional activator or loss of an inhibitor or suppressor (Cleary ML (1992) *Cancer Surv.* 15:89-104). Alternatively, gene fusion may produce chimeric loci with switched domains, such that the level of activation is no longer correct for the gene specificity of that factor.
- 10 The cellular response to infection or trauma is beneficial when gene expression is appropriate. However, when hyper-responsivity or another imbalance occurs for any reason, improper or insufficient regulation of gene expression may cause considerable tissue or organ damage. This damage is well documented in immunological responses to allergens, heart attack, stroke, and infections (Harrison's Principles of Internal Medicine, 13/e^o, (1994) 15 McGraw Hill, Inc. and Teton Data Systems Software). In addition, the accumulation of somatic mutations and the increasing inability to regulate cellular responses is seen in the prevalence of osteoarthritis and onset of other disorders associated with aging.

20 The discovery of new human regulatory protein molecules which are important in disease development and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention and treatment of diseases associated with cell proliferation, particularly immune responses and cancers.

SUMMARY OF THE INVENTION

The invention features substantially purified polypeptides, human regulatory molecules, collectively referred to as HRM and individually referred to as HRM-1 through 25 HRM-10, having at least one of the amino acid sequences selected from the group consisting of SEQ ID NOs:1-10.

The invention further provides isolated and substantially purified polynucleotide sequences encoding HRM. In a particular aspect, the polynucleotide is at least one the nucleotide sequences selected from the group consisting of SEQ ID NOs:11-20.

30 In addition, the invention provides a polynucleotide sequence, or fragment thereof, which hybridizes under stringent conditions to any of the polynucleotide sequences of SEQ ID NOs:11-20. In another aspect the invention provides compositions comprising isolated

and purified polynucleotide sequences of SEQ ID NOs:11-20 or fragments thereof.

The invention further provides a polynucleotide sequence comprising the complement or fragments thereof of any one of the polynucleotide sequences encoding HRM. In another aspect the invention provides compositions comprising isolated and purified polynucleotide sequences comprising the complements of SEQ ID NOs:11-20 or fragments thereof.

The present invention further provides an expression vector containing at least a fragment of any one of the polynucleotide sequences of SEQ ID NOs:11-20. In yet another aspect, the expression vector containing the polynucleotide sequence is contained within a host cell.

10 The invention also provides a method for producing a polypeptide or a fragment thereof, the method comprising the steps of: a) culturing the host cell containing an expression vector containing at least a fragment of the polynucleotide sequence encoding an HRM under conditions suitable for the expression of the polypeptide; and b) recovering the polypeptide from the host cell culture.

15 The invention also provides a pharmaceutical composition comprising a substantially purified HRM in conjunction with a suitable pharmaceutical carrier.

The invention also provides a purified antagonist of HRM. In one aspect the invention provides a purified antibody which binds to an HRM.

Still further, the invention provides a purified agonist of HRM.

20 The invention also provides a method for treating or preventing a cancer comprising administering to a subject in need of such treatment an effective amount of a pharmaceutical composition containing HRM.

25 The invention also provides a method for treating or preventing a cancer comprising administering to a subject in need of such treatment an effective amount of an antagonist of HRM.

The invention also provides a method for treating or preventing an immune response associated with the increased expression or activity of HRM comprising administering to a subject in need of such treatment an effective amount of an antagonist of HRM.

30 The invention also provides a method for stimulating cell proliferation comprising administering to a cell an effective amount of purified HRM.

The invention also provides a method for detecting a polynucleotide which encodes a human regulatory molecule in a biological sample comprising the steps of: a) hybridizing a

polynucleotide sequence complementary to a polynucleotide encoding HRM to nucleic acid material of a biological sample, thereby forming a hybridization complex; and b) detecting the hybridization complex, wherein the presence of the complex correlates with the presence of a polynucleotide encoding the human regulatory molecule in the biological sample.

5 The invention also provides a microarray which contains at least a fragment of at least one of the polynucleotide sequences encoding HRM. In a particular aspect, the microarray contains at least a fragment of at least one of the sequences selected from the group consisting of SEQ ID NOs:11-20.

10 The invention also provides a method for the simultaneous detection of the levels of expression of polynucleotides which encode human regulatory molecules in a biological sample comprising the steps of: a) hybridizing said microarray to labeled complementary nucleotides of a biological sample, comprising at least a fragment of at least one of the polynucleotides encoding HRM, thereby forming hybridization complexes; and b) quantifying expression, wherein the signal produced by the hybridization complexes 15 correlates with expression of particular polynucleotides encoding human regulatory molecules in the biological sample. In a preferred embodiment, prior to hybridization, the nucleic acid material of the biological sample is amplified and labeled by the polymerase chain reaction.

DESCRIPTION OF THE INVENTION

20 Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular methodology, protocols, cell lines, vectors, and reagents described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

25 It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to "a host cell" includes a plurality of such host cells, reference to the "antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

30 Unless defined otherwise, all technical and scientific terms used herein have the same meanings commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein

can be used in the practice or testing of the present invention, the preferred methods, devices, and materials are now described. All publications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the cell lines, vectors, arrays and methodologies which are reported in the publications which might be used in connection with 5 the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

DEFINITIONS

HRM refers to the amino acid sequences of substantially purified HRM obtained from any species, particularly mammalian, including bovine, ovine, porcine, murine, equine, 10 and preferably human, from any source whether natural, synthetic, semi-synthetic, or recombinant.

"Agonist" refers to a molecule which, when bound to HRM, increases or prolongs the duration of the effect of HRM. Agonists may include proteins, nucleic acids, carbohydrates, or any other molecules which bind to and modulate the effect of HRM.

15 An "allele" or "allelic sequence" is an alternative form of the gene encoding HRM. Alleles may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or polypeptides whose structure or function may or may not be altered. Any given natural or recombinant gene may have none, one, or many allelic forms. Common mutational changes which give rise to alleles are generally ascribed to natural deletions, 20 additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

"Altered" nucleic acid sequences encoding HRM include those with deletions, insertions, or substitutions of different nucleotides resulting in a polynucleotide that encodes the same or a functionally equivalent HRM. Included within this definition are 25 polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding HRM, and improper or unexpected hybridization to alleles, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding HRM. The encoded protein may also be "altered" and contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in 30 a functionally equivalent HRM. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the biological or immunological activity of

HRM is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid; positively charged amino acids may include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values may include leucine, isoleucine, and valine, glycine and alanine, asparagine and glutamine, serine and 5 threonine, and phenylalanine and tyrosine.

“Amino acid sequence” refers to an oligopeptide, peptide, polypeptide, or protein sequence, and fragment thereof, and to naturally occurring or synthetic molecules. Fragments of HRM are preferably about 5 to about 15 amino acids in length and retain the biological activity or the immunological activity of HRM. Where “amino acid sequence” is recited 10 herein to refer to an amino acid sequence of a naturally occurring protein molecule, amino acid sequence, and like terms, are not meant to limit the amino acid sequence to the complete, native amino acid sequence associated with the recited protein molecule.

“Amplification” refers to the production of additional copies of a nucleic acid sequence and is generally carried out using polymerase chain reaction (PCR) technologies 15 well known in the art

“Antagonist” refers to a molecule which, when bound to HRM, decreases the amount or the duration of the effect of the biological or immunological activity of HRM. Antagonists may include proteins, nucleic acids, carbohydrates, or any other molecules which decrease the effect of HRM.

“Antibody” refers to intact molecules as well as fragments thereof, such as Fa, F(ab')₂, and Fv, which are capable of binding the epitopic determinant. Antibodies that bind HRM polypeptides can be prepared using intact polypeptides or fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal can be derived from the translation of RNA or synthesized chemically and can be 20 conjugated to a carrier protein, if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin and thyroglobulin, keyhole limpet hemocyanin. The coupled peptide is then used to immunize the animal (e.g., a mouse, a rat, or a rabbit).

“Antigenic determinant” refers to that fragment of a molecule (i.e., an epitope) that 30 makes contact with a particular antibody. When a protein or fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to a given region or three-dimensional structure on the

protein; these regions or structures are referred to as antigenic determinants. An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

“Antisense” refers to any composition containing nucleotide sequences which are 5 complementary to a specific DNA or RNA sequence. The term “antisense strand” is used in reference to a nucleic acid strand that is complementary to the “sense” strand. Antisense molecules include peptide nucleic acids and may be produced by any method including synthesis or transcription. Once introduced into a cell, the complementary nucleotides combine with natural sequences produced by the cell to form duplexes and block either 10 transcription or translation. The designation “negative” is sometimes used in reference to the antisense strand, and “positive” is sometimes used in reference to the sense strand.

“Biologically active” refers to a protein having structural, regulatory, or biochemical 15 functions of a naturally occurring molecule. Likewise, “immunologically active” refers to the capability of the natural, recombinant, or synthetic HRM, or any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific 20 antibodies.

“Complementary” or “complementarity” refer to the natural binding of 25 polynucleotides under permissive salt and temperature conditions by base-pairing. For example, the sequence “A-G-T” binds to the complementary sequence “T-C-A”. Complementarity between two single-stranded molecules may be “partial”, in which only some of the nucleic acids bind, or it may be complete when total complementarity exists between the single stranded molecules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands. This is of particular importance in amplification reactions, which depend upon 30 binding between nucleic acids strands and in the design and use of PNA molecules.

A “composition comprising a given polynucleotide sequence” refers broadly to any composition containing the given polynucleotide sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding HRM (SEQ ID NOS:11-20) or fragments thereof may be employed as hybridization 35 probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., SDS) and other components

(e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus" refers to a nucleic acid sequence which has been resequenced to resolve uncalled bases, has been extended using XL-PCR kit (Perkin Elmer, Norwalk CT) in the 5' and/or the 3' direction and resequenced, or has been assembled from the overlapping 5 sequences of more than one Incyte Clone using a computer program for fragment assembly (e.g., GELVIEW Fragment Assembly system, GCG, Madison WI). Some sequences have been both extended and assembled to produce the consensus sequence.

The phrase "correlates with expression of a polynucleotide" indicates that the detection of the presence of a ribonucleic acid that is similar to a polynucleotide encoding an 10 HRM by northern analysis is indicative of the presence of mRNA encoding HRM in a sample and thereby correlates with expression of the transcript from the polynucleotide encoding the protein.

"HRM" refers to any or all of the human polypeptides, HRM-1 through HRM-10.

"Deletion" refers to a change in the amino acid or nucleotide sequence and results in 15 the absence of one or more amino acid residues or nucleotides.

"Derivative" refers to the chemical modification of a nucleic acid encoding or complementary to HRM or the encoded HRM. Such modifications include, for example, replacement of hydrogen by an alkyl, acyl, or amino group. A nucleic acid derivative encodes a polypeptide which retains the biological or immunological function of the natural molecule. 20 A derivative polypeptide is one which is modified by glycosylation, pegylation, or any similar process which retains the biological or immunological function of the polypeptide from which it was derived.

"Homology" refers to a degree of complementarity. There may be partial homology or complete homology (i.e., identity). A partially complementary sequence that at least 25 partially inhibits an identical sequence from hybridizing to a target nucleic acid is referred to using the functional term "substantially homologous." The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or northern blot, solution hybridization and the like) under conditions of low stringency. A substantially homologous sequence or hybridization probe 30 will compete for and inhibit the binding of a completely homologous sequence to the target sequence under conditions of low stringency. This is not to say that conditions of low stringency are such that non-specific binding is permitted; low stringency conditions require

that the binding of two sequences to one another be a specific (i.e., selective) interaction. The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% identity). In the absence of non-specific binding, the probe will not hybridize to the second non-
5 complementary target sequence.

Human artificial chromosomes (HACs) are linear microchromosomes which may contain DNA sequences of 10K to 10M in size and contain all of the elements required for stable mitotic chromosome segregation and maintenance.

“Humanized antibody” refers to antibody molecules in which amino acids have been
10 replaced in the non-antigen binding regions in order to more closely resemble a human antibody, while still retaining the original binding ability.

“Hybridization” refers to any process by which a strand of nucleic acid bonds with a complementary strand through base pairing.

“Hybridization complex” refers to a complex formed between two nucleic acid
15 sequences by virtue of the formation of hydrogen bonds between complementary G and C bases and between complementary A and T bases; these hydrogen bonds may be further stabilized by base stacking interactions. The two complementary nucleic acid sequences hydrogen bond in an antiparallel configuration. A hybridization complex may be formed in solution (e.g., C_{ot} or R_{ot} analysis) or between one nucleic acid sequence present in solution
20 and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

An “insertion” or “addition” refers to a change in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides,
25 respectively, as compared to the naturally occurring molecule.

“Microarray” refers to an array (or arrangement) of distinct oligonucleotides synthesized on a substrate, such as paper, nylon or other type of membrane, filter, gel, polymer, chip, glass slide, or any other suitable support.

“Modulate” refers to a change in the activity of HRM. For example, modulation may
30 cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional or immunological properties of HRM.

“Nucleic acid sequence” refers to an oligonucleotide, nucleotide, or polynucleotide,

and fragments thereof, and to DNA or RNA of genomic or synthetic origin which may be single- or double-stranded, and represent the sense or antisense strand. "Fragments" are those nucleic acid sequences which are greater than 60 nucleotides than in length, and most preferably includes fragments that are at least 100 nucleotides or at least 1000 nucleotides, 5 and at least 10,000 nucleotides in length.

"Oligonucleotide" refers to a nucleic acid sequence of at least about 6 nucleotides to about 60 nucleotides, preferably about 15 to 30 nucleotides, and more preferably about 20 to 25 nucleotides, which can be used in PCR amplification or hybridization assays. As used herein, oligonucleotide is substantially equivalent to the terms "amplimers", "primers", 10 "oligomers", and "probes", as commonly defined in the art.

"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least five nucleotides in length linked to a peptide backbone of amino acid residues which ends in lysine. The terminal lysine confers solubility to the composition. PNAs may be pegylated to extend their lifespan in the cell where they 15 preferentially bind complementary single stranded DNA and RNA and stop transcript elongation (Nielsen, P.E. et al. (1993) Anticancer Drug Des. 8:53-63).

"Portion", with regard to a protein (as in "a portion of a given protein"), refers to fragments of that protein. The fragments may range in size from five amino acid residues to the entire amino acid sequence minus one amino acid. Thus, a protein "comprising at least a 20 portion of the amino acid sequence of an HRM encompasses the full-length HRM and fragments thereof.

"Sample" is used in its broadest sense. A biological sample suspected of containing nucleic acid encoding HRM, or fragments thereto, or HRM itself may comprise a bodily fluid, extract from a cell, chromosome, organelle, or membrane isolated from a cell, a cell, 25 genomic DNA, RNA, or cDNA (in solution or bound to a solid support, a tissue, a tissue print, and the like.

"Specific binding" or "specifically binding" refers to that interaction between a protein or peptide and an agonist, an antibody and an antagonist. The interaction is dependent upon the presence of a particular structure (i.e., the antigenic determinant or epitope) of the 30 protein recognized by the binding molecule. For example, if an antibody is specific for epitope "A", the presence of a protein containing epitope A (or free, unlabeled A) in a reaction containing labeled "A" and the antibody will reduce the amount of labeled A bound

to the antibody.

- "Stringent conditions" or "stringency" refer to the conditions for hybridization as defined by the nucleic acid, salt, and temperature. These conditions are well known in the art and may be altered in order to identify or detect identical or related polynucleotide sequences.
- 5 Numerous equivalent conditions comprising either low or high stringency depend on factors such as the length and nature of the sequence (DNA, RNA, base composition), nature of the target (DNA, RNA, base composition), milieu (in solution or immobilized on a solid substrate), concentration of salts and other components (e.g., formamide, dextran sulfate and/or polyethylene glycol), and temperature of the reactions (within a range from about 5°C
- 10 below the melting temperature of the probe to about 20°C to 25°C below the melting temperature). One or more factors may be varied to generate conditions of either low or high stringency different from, but equivalent to, the above listed conditions.

- "Substantially purified" refers to nucleic or amino acid sequences that are removed from their natural environment, isolated or separated, and are at least 60% free, preferably 15 75% free, and most preferably 90% free from other components with which they are naturally associated.

A "substitution" refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

- "Transformation" describes a process by which exogenous DNA enters and changes a 20 recipient cell. It may occur under natural or artificial conditions using various methods well known in the art. Transformation may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method is selected based on the type of host cell being transformed and may include, but is not limited to, viral infection, electroporation, heat shock, lipofection, and particle bombardment. Such 25 "transformed" cells include stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome. They also include cells which transiently express the inserted DNA or RNA for limited periods of time.

- A "variant" of HRM refers to an amino acid sequence that is altered by one or more 30 amino acids. The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties, e.g., replacement of leucine with isoleucine. More rarely, a variant may have "nonconservative" changes, e.g., replacement of a glycine

with a tryptophan. Analogous minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, LASERGENE software

5 (DNASTAR Inc., Madison WI)

THE INVENTION

The invention is based on the discovery of human regulatory molecules (HRM) and the polynucleotides encoding HRM and on the use of these compositions for the diagnosis, prevention, or treatment of diseases associated with cell proliferation. Table 1 shows the 10 protein and nucleotide sequence identification numbers, protein abbreviation, Incyte Clone number, cDNA library, NCBI homolog and NCBI sequence identifier for each of the human regulatory molecules disclosed herein.

5 HRM-1 (SEQ ID NO:1) was identified in Incyte Clone 9476 from the HMC1NOT01 cDNA library using a computer search for amino acid sequence alignments. A consensus 15 sequence, SEQ ID NO:11, was derived from the extended and overlapping nucleic acid sequences: Incyte Clones 9476 (HMC1NOT01), 010403 (THP1PLB01), 495099 (HNT2NOT01), 1670783 (BMARNOT03), 1997203 (BRSTTUT03), and 2190637 (THYRTUT03).

In one embodiment, the invention encompasses a polypeptide comprising the amino 20 acid sequence of SEQ ID NO:1. HRM-1 is 456 amino acids in length and has a potential N glycosylation site at N385; 14 potential phosphorylation sites at T9, T12, S58, T74, T163, T139, S175, T211, T239, T272, S331, T367, T402, and S443; and an ATP/GTP binding 25 motif at G₇₀PPGTGKT77. HRM-1 has sequence homology with a S. cerevisiae protein (g755784) and is found in cDNA libraries which have dividing, cancerous or immortalized cells and are associated with immune response.

8 HRM-2 (SEQ ID NO:2) was identified in Incyte Clone 77180 from the SYNORAB01 cDNA library using a computer search for amino acid sequence alignments. A consensus 30 sequence, SEQ ID NO:12, was derived from the extended and overlapping nucleic acid sequences: Incyte Clones 077180 (SYNORAB01), 604706 (BRSTTUT01), 977901 (BRSTNOT02), 1870373 (SKINBIT01), and 2169441 (ENDCNOT03).

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:2. HRM-2 is 188 amino acids in length and has one potential

amidation site, Q170GKR; two potential N glycosylation sites at N60 and N68; and four potential phosphorylation sites at S70, T164, T166, and S183. HRM-2 has sequence homology with a S. cerevisiae protein (g5372) and is found in cDNA libraries which have dividing, cancerous or immortalized cells and are associated with immune response.

5 3 HRM-3 (SEQ ID NO:3) was identified in Incyte Clone 118160 from the MUSCNOT01 cDNA library using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO:13, was derived from the extended and overlapping nucleic acid sequences: Incyte Clones 118160 (MUSCNOT01), 323015 (EOSIHET02), and 1856519 (PROSNOT18).

10 In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:3. HRM-3 is 348 amino acids in length and has two potential N glycosylation sites at N150 and N317; 17 potential phosphorylation sites at T23, T45, S60, T126, S130, S140, S145, S151, S154, S158, S186, Y208, Y234, S217, T271, T303, and S327, and a transcription factor signature at C₃₁₀SKCKKKNCTYNQVQTRSA

15 DEPMTTFVLCNEC. HRM-3 has sequence homology with a Mus musculus protein (g220594) and is found in cDNA libraries which have secretory or immune associations.

21 HRM-4 (SEQ ID NO:4) was identified in Incyte Clone 933353 from the CERVNOT01 cDNA library using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO:14, was derived from the extended and overlapping nucleic acid sequences: Incyte Clones 928904 (BRAINOT04), 933353 (CERVNOT01), and 2452674 (ENDANOT01).

25 In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:4. HRM-4 is 201 amino acids in length and has one potential N glycosylation site at N82; five potential phosphorylation sites at T70, S83, S98, S154, and T187; and one tyrosine phosphatase motif at V₁₃₀HCKAGRSRSATM. HRM-4 has sequence homology with a C. elegans protein (g1657672) and is found in cDNA libraries associated with immune response.

24 HRM-5 (SEQ ID NO:5) was identified in Incyte Clone 1404643 from the LATRTUT02 cDNA library using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO:15, was derived from the extended and overlapping nucleic acid sequences: Incyte Clones 878243 (LUNGAST01), 1404643 (LATRTUT02), 1508343 (LUNGNOT14) and 2585156 (BRAITUT22).

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:5. HRM-5 is 239 amino acids in length and has four potential phosphorylation sites at S5, S89, S133, and T211. HRM-5 has sequence homology with a *C. elegans* protein (g459002) and is found in cDNA libraries associated with cell proliferation, 5 cancer and immune response.

30 HRM-6 (SEQ ID NO:6) was identified in Incyte Clone 1600438 from the BLADNOT03 cDNA library using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO:16, was derived from the extended and overlapping nucleic acid sequences: Incyte Clones 835283 (PROSNOT07), 1600044 (BLADNOT03), 1600438 10 (BLADNOT03), and 1922072 (BRSTTUT01).

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:6. HRM-6 is 419 amino acids in length and has one potential N glycosylation site at N161; twelve potential phosphorylation sites at T16, S57, T67, T83, S100, T107, S144, S206, T254, Y351, S412, and S414; a leucine zipper motif, 15 L₃₈NEAGDDLEAVAKFLDSTGSRL; and an ATP/GTP binding motif, A₃₈₅HVAKGKS. HRM-6 has sequence homology with human KIAA0005 (g286001) and is found in cDNA libraries associated with secretion and cancer.

33 HRM-7 (SEQ ID NO:7) was identified in Incyte Clone 1600518 from the BLADNOT03 cDNA library using a computer search for amino acid sequence alignments. A 20 consensus sequence, SEQ ID NO:17, was derived from the extended and overlapping nucleic acid sequences: Incyte Clones 389679 (THYMNOT02), 1600518 (BLADNOT03), 2055734 (BEPINOT01), 2102793 (BRAITUT02), and 2509270 (CONUTUT01).

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:7. HRM-7 is 376 amino acids in length and has one potential N 25 glycosylation site at N161 and 14 potential phosphorylation sites at T30, S65, S75, S95, S106, T134, S159, S224, T228, T250, T292, S299, T303, and S323 and a glycosaminoglycan motif, S14GPG. HRM-7 has sequence homology with a *C. elegans* protein (g790405) and is found in cDNA libraries associated with immune response, secretion, and cancer.

45 HRM-8 (SEQ ID NO:8) was identified in Incyte Clone 2515476 from the 30 LIVRTUT04 cDNA library using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO:18, was derived from the extended and overlapping nucleic acid sequences: Incyte clones 18414 (HUVELPB01), 78341 (SYNORAB01), 143277

(TLYMNOR01), 181574 (PLACNOB01), 832996 (PROSTUT04), 962753 (BRSTTUT03), 1413604 (BRAINOT12), and 2515476 (LIVRTUT04).

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:8. HRM-8 is 811 amino acids in length and has three potential 5 amidation sites at G₁₁₃GRR, W₁₆₅GKR, and G₇₉₀GKK; four potential N glycosylation sites at N22, N56, N79, and N145; 24 potential phosphorylation sites at T11, S13, S30, S60, Y71, S81, S85, S86, S103, S254, S256, T377, S388, S425, S456, S487, T544, S552, S574, T659, S678, S702, S746, and S753; a potential glycosaminoglycan site, S₁₆₀GHG; and a potential zinc finger motif at C₂₄₀GHIFCWACI. HRM-8 has sequence homology with human 10 KIAA0262 (g1665790) and is found in cDNA libraries involved in cell proliferation, secretion, cancer, and immune response.

46 HRM-9 (SEQ ID NO:9) was identified in Incyte Clone 2754573 from the THP1AZS08 cDNA library using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO:19, was derived from the extended and overlapping nucleic 15 acid sequences: Incyte Clones 263630 (HNT2AGT01), 412307 (BRSTNOT01), 491644 (HNT2AGT01), 1253094 (LUNGFET03), 2270603 (PROSNON01), 2280508 (PROSNON01), 2375670 (ISLTNOT01), 2754573 (THP1AZS08), and 3151587 (ADRENON04).

In one embodiment, the invention encompasses a polypeptide comprising the amino 20 acid sequence of SEQ ID NO:9. HRM-9 is 352 amino acids in length and has two potential N glycosylation sites at N141 and N294, and thirteen potential phosphorylation sites at S8, T67, T106, T110, T121, S122, S169, S206, T210, S215, S256, S260, and T296. HRM-9 has sequence homology with human RNA binding protein (g478990) and is found in cDNA libraries involved in cell proliferation, secretion, and immune response.

25 47 HRM-10 (SEQ ID NO:10) was identified in Incyte Clone 2926777 from the TLYMN04 cDNA library using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO:20, was derived from the extended and overlapping nucleic acid sequences: Incyte Clones 040208 (TBLYN01), 900242 (BRSTTUT03), 963500 (BRSTTUT03), 1996474 (BRSTTUT03), and 2926777 (TLYMN04).

30 In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:10. HRM-10 is 432 amino acids in length and has a potential N glycosylation site at N417 and 24 potential phosphorylation sites at T51, S73, T122, T133,

S177, S206, T226, T238, S293, S300, S304, S309, T325, S333, S339, S353, S360, Y361, S384, S390, T403, T412, T419, and S425. HRM-10 has sequence homology with a C. elegans protein (g687823) and is found in cDNA libraries involved in cell proliferation, secretion, cancer, and immune response.

5 The invention also encompasses HRM variants which retain the biological or functional activity of HRM. A preferred HRM variant is one having at least 80%, and more preferably 90%, amino acid sequence identity to the HRM amino acid sequence. A most preferred HRM variant is one having at least 95% amino acid sequence identity to an HRM disclosed herein (SEQ ID NOS:1-10).

10 The invention also encompasses polynucleotides which encode HRM. Accordingly, any nucleic acid sequence which encodes the amino acid sequence of HRM can be used to produce recombinant molecules which express HRM. In a particular embodiment, the invention encompasses a polynucleotide consisting of a nucleic acid sequence selected from the group consisting of SEQ ID NOS:11-20.

15 It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of nucleotide sequences encoding HRM, some bearing minimal homology to the nucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of nucleotide sequence that could be made by selecting combinations based on possible codon choices.

20 These combinations are made in accordance with the standard triplet genetic code as applied to the nucleotide sequence of naturally occurring HRM, and all such variations are to be considered as being specifically disclosed.

25 Although nucleotide sequences which encode HRM and its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring HRM under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding HRM or its derivatives possessing a substantially different codon usage. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the 30 nucleotide sequence encoding HRM and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences, or fragments thereof, which encode HRM and its derivatives, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents that are well known in the art. Moreover, synthetic chemistry may be 5 used to introduce mutations into a sequence encoding HRM or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed nucleotide sequences, and in particular, those shown in SEQ ID NOS:11-20, under various conditions of stringency as taught in Wahl, G.M. and S.L. Berger (1987; Methods Enzymol. 152:399-407) and Kimmel, A.R. (1987; Methods Enzymol. 10 152:507-511).

Methods for DNA sequencing which are well known and generally available in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical Corp, Cleveland OH), TAQ polymerase (Perkin Elmer), thermostable T7 15 polymerase (Amersham Pharmacia, Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system marketed by Life Technologies (Gaithersburg MD). Preferably, the process is automated with machines such as the Hamilton Micro Lab 2200 (Hamilton, Reno NV), Peltier Thermal Cycler (PTC200; MJ Research, Watertown MA) and the ABI Catalyst and 373 and 377 DNA 20 Sequencers (Perkin Elmer).

The nucleic acid sequences encoding HRM may be extended utilizing a partial nucleotide sequence and employing various methods known in the art to detect upstream sequences such as promoters and regulatory elements. For example, one method which may be employed, "restriction-site" PCR, uses universal primers to retrieve unknown sequence 25 adjacent to a known locus (Sarkar, G. (1993) PCR Methods Applic. 2:318-322). In particular, genomic DNA is first amplified in the presence of primer to a linker sequence and a primer specific to the known region. The amplified sequences are then subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and 30 sequenced using reverse transcriptase.

Inverse PCR may also be used to amplify or extend sequences using divergent primers based on a known region (Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186). The primers

may be designed using commercially available software such as OLIGO 4.06 Primer Analysis software (National Biosciences Inc., Plymouth MN), or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68°-72° C. The method uses several restriction enzymes to 5 generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.

Another method which may be used is capture PCR which involves PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA (Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119). In this 10 method, multiple restriction enzyme digestions and ligations may also be used to place an engineered double-stranded sequence into an unknown fragment of the DNA molecule before performing PCR.

Another method which may be used to retrieve unknown sequences is that of Parker, J.D. et al. (1991: Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested 15 primers, and PROMOTERFINDER libraries to walk genomic DNA (Clontech, Palo Alto CA). This process avoids the need to screen libraries and is useful in finding intron/exon junctions. When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. Also, random-primed libraries are preferable, in that they will contain more sequences which contain the 5' regions of genes. Use of a 20 randomly primed library may be especially preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In 25 particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser activated, and detection of the emitted wavelengths by a charge coupled device camera. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Perkin Elmer) and the entire process from loading of 30 samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for the sequencing of small pieces of DNA which might be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode HRM may be used in recombinant DNA molecules to direct expression of HRM, fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced, and these sequences may be used to clone and express HRM.

As will be understood by those of skill in the art, it may be advantageous to produce HRM-encoding nucleotide sequences possessing non-naturally occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can be selected to 10 increase the rate of protein expression or to produce an RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter HRM encoding sequences for a variety of reasons, 15 including but not limited to, alterations which modify the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, site-directed mutagenesis may be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice 20 variants, introduce mutations, and so forth.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding HRM may be ligated to a heterologous sequence to encode a fusion protein. For example, to screen peptide libraries for inhibitors of HRM activity, it may be useful to encode a chimeric HRM protein that can be recognized by a commercially available 25 antibody. A fusion protein may also be engineered to contain a cleavage site located between the HRM encoding sequence and the heterologous protein sequence, so that HRM may be cleaved and purified away from the heterologous moiety.

In another embodiment, sequences encoding HRM may be synthesized, in whole or in part, using chemical methods well known in the art. (See Caruthers, M.H. et al. (1980) Nucl. 30 Acids Res. Symp. Ser. 215-223; Horn, T. et al. (1980) Nucl. Acids Res. Symp. Ser. 225-232.) Alternatively, the protein itself may be produced using chemical methods to synthesize the amino acid sequence of HRM, or a fragment thereof. For example, peptide synthesis can be

performed using various solid-phase techniques (Roberge, J.Y. et al. (1995) *Science* 269:202-204) and automated synthesis may be achieved, for example, using the ABI 431A Peptide synthesizer (Perkin Elmer).

The newly synthesized peptide may be substantially purified by preparative high 5 performance liquid chromatography (e.g., Creighton, T. (1983) Proteins, Structures and Molecular Principles, WH Freeman and Co., New York NY). The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure; Creighton, *supra*). Additionally, the amino acid sequence of HRM, or any part thereof, may be altered during direct synthesis and/or combined using chemical 10 methods with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

In order to express a biologically active HRM, the nucleotide sequences encoding 15 HRM or functional equivalents, may be inserted into appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence.

Methods which are well known to those skilled in the art may be used to construct 20 expression vectors containing sequences encoding HRM and appropriate transcriptional and translational control elements. These methods include *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* genetic recombination. Such techniques are described in 25 Sambrook, J. et al. (1989; Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY) and Ausubel, F.M. et al. (1989; Current Protocols in Molecular Biology, John Wiley & Sons, New York NY).

A variety of expression vector/host systems may be utilized to contain and express 25 sequences encoding HRM. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (e.g., baculovirus); plant cell systems transformed with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. The 30 invention is not limited by the host cell employed.

The "control elements" or "regulatory sequences" are those non-translated regions of the vector--enhancers, promoters, 5' and 3' untranslated regions--which interact with host

- cellular proteins to carry out transcription and translation. Such elements may vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible 5 promoters such as the hybrid lacZ promoter of the BLUESCRIPT phagemid (Stratagene, LaJolla CA) or pSPORT1 plasmid (Life Technologies) and the like may be used. The baculovirus polyhedrin promoter may be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (e.g., heat shock, RUBISCO; and storage protein genes) or from plant viruses (e.g., viral promoters or leader sequences) may be cloned into the vector. 10 In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of the sequence encoding HRM, vectors based on SV40 or EBV may be used with an appropriate selectable marker.

In bacterial systems, a number of expression vectors may be selected depending upon 15 the use intended for HRM. For example, when large quantities of HRM are needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified may be used. Such vectors include, but are not limited to, the multifunctional *E. coli* cloning and expression vectors such as BLUESCRIPT (Stratagene), in which the sequence encoding HRM may be ligated into the vector in frame with sequences for the 20 amino-terminal Met and the subsequent 7 residues of β -galactosidase so that a hybrid protein is produced; pIN vectors (Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509); and the like. pGEX vectors (Promega, Madison WI) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by 25 adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems may be designed to include heparin, thrombin, or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

In the yeast, *Saccharomyces cerevisiae*, a number of vectors containing constitutive or 30 inducible promoters such as alpha factor, alcohol oxidase, and PGH may be used. For reviews, see Ausubel et al. (supra) and Grant et al. (1987: Methods Enzymol. 153:516-544).

In cases where plant expression vectors are used, the expression of sequences

encoding HRM may be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV may be used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock 5 promoters may be used (Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105). These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. Such techniques are described in a number of generally available reviews (McGraw Hill Yearbook of Science and Technology 10 (1992) McGraw Hill, New York NY; pp. 191-196).

An insect system may also be used to express HRM. For example, in one such system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in Spodoptera frugiperda cells or in Trichoplusia larvae. The sequences encoding HRM may be cloned into a non-essential region of the virus, such as the polyhedrin 15 gene, and placed under control of the polyhedrin promoter. Successful insertion of HRM will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses may then be used to infect, for example, S. frugiperda cells or Trichoplusia larvae in which HRM may be expressed (Engelhard, E.K. et al. (1994) Proc. Nat. Acad. Sci. 91:3224-3227).

20 In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding HRM may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain a viable virus which is capable of expressing HRM in infected 25 host cells (Logan, J. and Shenk, T. (1984) Proc. Natl. Acad. Sci. 81:3655-3659). In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.

Human artificial chromosomes (HACs) may also be employed to deliver larger 30 fragments of DNA than can be contained and expressed in a plasmid. HACs of 6 to 10M are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes (Harrington, J.J. et al. (1997) Nat Genet. 15:345-355).

Specific initiation signals may also be used to achieve more efficient translation of sequences encoding HRM. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding HRM, its initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or 5 translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including the ATG initiation codon should be provided. Furthermore, the initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The 10 efficiency of expression may be enhanced by the inclusion of enhancers which are appropriate for the particular cell system which is used, such as those described in the literature (Scharf, D. et al. (1994) *Results Probl. Cell Differ.* 20:125-162).

In addition, a host cell strain may be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such 15 modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be used to facilitate correct insertion, folding and/or function. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38), 20 are available from the American Type Culture Collection (ATCC; Bethesda MD) and may be chosen to ensure the correct modification and processing of the foreign protein.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express HRM may be transformed using 25 expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably 30 transformed cells may be proliferated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines.

These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler, M. et al. (1977) *Cell* 11:223-32) and adenine phosphoribosyltransferase (Lowy, I. et al. (1980) *Cell* 22:817-23) genes which can be employed in tk⁻ or aprt⁻ cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, dhfr which confers resistance to methotrexate (Wigler, M. et al. (1980) *Proc. Natl. Acad. Sci.* 77:3567-70); npt, which confers resistance to the aminoglycosides neomycin and G-418 (Colbere-Garapin, F. et al (1981) *J. Mol. Biol.* 150:1-14) and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (McGraw Hill Yearbook of Science and Technology, supra). Additional selectable genes have been described, for example, trpB, which allows cells to utilize indole in place of tryptophan, or hisD, which allows cells to utilize histinol in place of histidine (Hartman, S.C. and R.C. Mulligan (1988) *Proc. Natl. Acad. Sci.* 85:8047-51). Recently, the use of visible markers has gained popularity with such markers as anthocyanins, β glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, being widely used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes, C.A. et al. (1995) *Methods Mol. Biol.* 55:121-131).

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, its presence and expression may need to be confirmed. For example, if the sequence encoding HRM is inserted within a marker gene sequence, transformed cells containing sequences encoding HRM can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding HRM under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

Alternatively, host cells which contain the nucleic acid sequence encoding HRM and express HRM may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein.

The presence of polynucleotide sequences encoding HRM can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes or fragments or fragments of polynucleotides encoding HRM. Nucleic acid amplification based assays involve the use of oligonucleotides or oligomers based on the sequences encoding HRM to

detect transformants containing DNA or RNA encoding HRM.

A variety of protocols for detecting and measuring the expression of HRM, using either polyclonal or monoclonal antibodies specific for the protein are known in the art.

Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA),

5 and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on HRM is preferred, but a competitive binding assay may be employed. These and other assays are described, among other places, in Hampton, R. et al. (1990; Serological Methods, a Laboratory Manual, APS Press, St Paul MN) and Maddox, D.E. et al. (1983; *J. Exp. Med.* 158:1211-1216).

10 A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding HRM include oligolabeling, nick translation, end-labeling or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding HRM, or any fragments 15 thereof may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits (Amersham Pharmacia, Promega; and US Biochemical Corp.). Suitable reporter 20 molecules or labels, which may be used for ease of detection, include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding HRM may be cultured under conditions suitable for the expression and recovery of the protein from cell culture.

25 The protein produced by a transformed cell may be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode HRM may be designed to contain signal sequences which direct secretion of HRM through a prokaryotic or eukaryotic cell membrane. Other constructions may be used to join sequences encoding 30 HRM to nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on

immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle WA). The inclusion of cleavable linker sequences such as those specific for Factor XA or enterokinase (Invitrogen, San Diego CA) between the 5 purification domain and HRM may be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing HRM and a nucleic acid encoding 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification on IMAC (immobilized metal ion affinity chromatography as described in Porath, J. et al. (1992, *Prot. Exp. Purif.* 3: 263-281) while the 10 enterokinase cleavage site provides a means for purifying HRM from the fusion protein. A discussion of vectors which contain fusion proteins is provided in Kroll, D.J. et al. (1993; *DNA Cell Biol.* 12:441-453).

In addition to recombinant production, fragments of HRM may be produced by direct 15 peptide synthesis using solid-phase techniques (Merrifield J. (1963) *J. Am. Chem. Soc.* 85:2149-2154). Protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide synthesizer (Perkin Elmer). Various fragments of HRM may be chemically synthesized separately and combined using chemical methods to produce the full length 20 molecule.

20 THERAPEUTICS

Chemical and structural homology exists among the human regulatory proteins of the 25 invention. The expression of HRM is closely associated with cell proliferation. Therefore, in cancers or immune disorders where HRM is an activator, transcription factor, or enhancer, and is promoting cell proliferation; it is desirable to decrease the expression of HRM. In cancers where HRM is an inhibitor or suppressor and is controlling or decreasing cell proliferation, it is desirable to provide the protein or to increase the expression of HRM.

In one embodiment, where HRM is an inhibitor, HRM or a fragment or derivative thereof may be administered to a subject to prevent or treat a cancer such as adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, and teratocarcinoma. Such cancers 30 include, but are not limited to, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis,

thymus, thyroid, and uterus.

In another embodiment, an agonist which is specific for HRM may be administered to a subject to prevent or treat a cancer including, but not limited to, those cancers listed above.

In another further embodiment, a vector capable of expressing HRM, or a fragment or 5 a derivative thereof, may be administered to a subject to prevent or treat a cancer including, but not limited to, those cancers listed above.

In a further embodiment where HRM is promoting cell proliferation, antagonists which decrease the expression or activity of HRM may be administered to a subject to 10 prevent or treat a cancer such as adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, and teratocarcinoma. Such cancers include, but are not limited to, cancers of the 15 adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus. In one aspect, antibodies which specifically bind HRM may be used directly as an antagonist or indirectly as 20 a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissue which express HRM.

In another embodiment, a vector expressing the complement of the polynucleotide encoding HRM may be administered to a subject to treat or prevent a cancer including, but not limited to, those cancers listed above.

20 In yet another embodiment where HRM is promoting leukocyte activity or proliferation, antagonists which decrease the activity of HRM may be administered to a subject to prevent or treat an immune response. Such responses may be associated with AIDS, Addison's disease, adult respiratory distress syndrome, allergies, anemia, asthma, atherosclerosis, bronchitis, cholecystitus, Crohn's disease, ulcerative colitis, atopic dermatitis, 25 dermatomyositis, diabetes mellitus, emphysema, atrophic gastritis, glomerulonephritis, gout, Graves' disease, hypereosinophilia, irritable bowel syndrome, lupus erythematosus, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, rheumatoid arthritis, scleroderma, Sjögren's syndrome, and autoimmune thyroiditis; complications of cancer, hemodialysis, extracorporeal 30 circulation; viral, bacterial, fungal, parasitic, protozoal, and helminthic infections; and trauma. In one aspect, antibodies which specifically bind HRM may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical

WO 99/15658

agent to cells or tissue which express HRM.

In another embodiment, a vector expressing the complement of the polynucleotide encoding HRM may be administered to a subject to treat or prevent an immune response including, but not limited to, those listed above

5 In one further embodiment, HRM or a fragment or derivative thereof may be added to cells to stimulate cell proliferation. In particular, HRM may be added to a cell in culture or cells in vivo using delivery mechanisms such as liposomes, viral based vectors, or electroinjection for the purpose of promoting cell proliferation and tissue or organ regeneration. Specifically, HRM may be added to a cell, cell line, tissue or organ culture in vitro or ex vivo to stimulate cell proliferation for use in heterologous or autologous 10 transplantation. In some cases, the cell will have been preselected for its ability to fight an infection or a cancer or to correct a genetic defect in a disease such as sickle cell anemia, β thalassemia, cystic fibrosis, or Huntington's chorea.

15 In another embodiment, an agonist which is specific for HRM may be administered to a cell to stimulate cell proliferation, as described above.

15 In another embodiment, a vector capable of expressing HRM, or a fragment or a derivative thereof, may be administered to a cell to stimulate cell proliferation, as described above.

20 In other embodiments, any of the therapeutic proteins, antagonists, antibodies, agonists, complementary sequences or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. 25 Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

Antagonists or inhibitors of HRM may be produced using methods which are generally known in the art. In particular, purified HRM may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind HRM.

30 Antibodies to HRM may be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fab fragments, and fragments produced by a Fab expression library. Neutralizing

antibodies, (i.e., those which inhibit dimer formation) are especially preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others, may be immunized by injection with HRM or any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, 5 various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli 10 Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to HRM have an amino acid sequence consisting of at least five amino acids and more 15 preferably at least 10 amino acids. It is also preferable that they are identical to a portion of the amino acid sequence of the natural protein, and they may contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of HRM amino acids may 15 be fused with those of another protein such as keyhole limpet hemocyanin and antibody produced against the chimeric molecule.

Monoclonal antibodies to HRM may be prepared using any technique which provides 20 for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and 25 the EBV-hybridoma technique (Kohler, G. et al. (1975) *Nature* 256:495-497; Kozbor, D. et al. (1985) *J. Immunol. Methods* 81:31-42; Cote, R.J. et al. (1983) *Proc. Natl. Acad. Sci.* 80:2026-2030; and Cole, S.P. et al. (1984) *Mol. Cell Biol.* 62:109-120).

In addition, techniques developed for the production of "chimeric antibodies", the 25 splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity can be used (Morrison, S.L. et al. 20 (1984) *Proc. Natl. Acad. Sci.* 81:6851-6855; Neuberger, M.S. et al. (1984) *Nature* 312:604-608; and Takeda, S. et al. (1985) *Nature* 314:452-454). Alternatively, techniques 30 described for the production of single chain antibodies may be adapted, using methods known in the art, to produce HRM-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries (Burton D.R. (1991) *Proc. Natl. Acad. Sci.*

88:11120-3).

Antibodies may also be produced by inducing *in vivo* production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature (Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. 86: 3833-3837; Winter, G. et al. (1991) Nature 349:293-299).

5 Antibody fragments which contain specific binding sites for HRM may also be generated. For example, such fragments include, but are not limited to, the F(ab')2 fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab')2 fragments.

10 Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (Huse, W.D. et al. (1989) Science 254:1275-1281).

15 Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between HRM and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering HRM epitopes is preferred, but a competitive binding assay may also be employed (Maddox, *supra*).

20 In another embodiment of the invention, the polynucleotides encoding HRM, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, the complement of the polynucleotide encoding HRM may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding HRM. Thus, complementary molecules or fragments may be used to modulate HRM activity, or to achieve 25 regulation of gene function. Such technology is now well known in the art, and sense or antisense oligonucleotides or larger fragments, can be designed from various locations along the coding or control regions of sequences encoding HRM.

30 Expression vectors derived from retroviruses, adenovirus, herpes or vaccinia viruses, or from various bacterial plasmids may be used for delivery of nucleotide sequences to the targeted organ, tissue or cell population. Methods which are well known to those skilled in the art can be used to construct vectors which will express nucleic acid sequence which is

WO 99/15658

complementary to the polynucleotides of the gene encoding HRM. These techniques are described both in Sambrook et al. (supra) and in Ausubel et al. (supra).

5 Genes encoding HRM can be turned off by transforming a cell or tissue with expression vectors which express high levels of a polynucleotide or fragment thereof which encodes HRM. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until they are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector and even longer if appropriate replication elements are part of the vector system.

10 As mentioned above, modifications of gene expression can be obtained by designing complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5' or regulatory regions of the gene encoding HRM (signal sequence, promoters, enhancers, and introns). Oligonucleotides derived from the transcription initiation site, e.g., between positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved 15 using "triple helix" base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature (Gee, J.E. et al. (1994) In: Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing Co., Mt. 20 Kisco, NY). The complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

25 Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Examples which may be used include engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding HRM.

30 Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for secondary structural features which may render the

oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be 5 prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding HRM. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such 10 as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA constitutively or inducibly can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at 15 the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

20 Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections or polycationic amino polymers (Goldman, C.K. et al. (1997) *Nature Biotechnology* 15:462-66; incorporated herein 25 by reference) may be achieved using methods which are well known in the art.

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

An additional embodiment of the invention relates to the administration of a 30 pharmaceutical composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of HRM, antibodies to HRM, mimetics, agonists, antagonists, or inhibitors of HRM.

WO 99/15658

The compositions may be administered alone or in combination with at least one other agent, such as stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs or hormones.

5 The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

10 In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co.,

15 Easton PA).

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for 20 ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combination of active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are carbohydrate or protein fillers, such as sugars, 25 including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums including arabic and tragacanth; and proteins such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium 30 alginate.

Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel,

polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Non-lipid polycationic amino polymers may also be used for delivery. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred preparation may be a lyophilized powder which may contain any or all of the following: 1-50 mM histidine, 0.1%-2% sucrose, and 2-7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

WO 99/15658

After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of HRM, such labeling would include amount, frequency, and method of administration.

5 Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

10 For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models, usually mice, rabbits, dogs, or pigs. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

15 A therapeutically effective dose refers to that amount of active ingredient, for example HRM or fragments thereof, antibodies of HRM, agonists, antagonists or inhibitors of HRM, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio between therapeutic and toxic effects is the therapeutic index, and it can be expressed as the ratio, ED50/LD50.

20 Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.

25 The exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, general health of the subject, age, 30 weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or once

WO 99/15658

every two weeks depending on half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

DIAGNOSTICS

In another embodiment, antibodies which specifically bind HRM may be used for the diagnosis of conditions or diseases characterized by expression of HRM, or in assays to monitor patients being treated with HRM, agonists, antagonists or inhibitors. The antibodies useful for diagnostic purposes may be prepared in the same manner as those described above for therapeutics. Diagnostic assays for HRM include methods which utilize the antibody and a label to detect HRM in human body fluids or extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by joining them, either covalently or non-covalently, with a reporter molecule. A wide variety of reporter molecules which are known in the art may be used, several of which are described above.

A variety of protocols including ELISA, RIA, and FACS for measuring HRM are known in the art and provide a basis for diagnosing altered or abnormal levels of HRM expression. Normal or standard values for HRM expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibody to HRM under conditions suitable for complex formation. The amount of standard complex formation may be quantified by various methods, but preferably by photometric means. Quantities of HRM expressed in subject, control and disease, samples are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding HRM may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of HRM may be correlated with disease. The diagnostic assay may be used to distinguish between absence, presence, and excess expression of HRM, and to monitor

regulation of HRM levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding HRM or closely related molecules, may be used to identify nucleic acid sequences which encode HRM. The 5 specificity of the probe, whether it is made from a highly specific region, e.g., 10 unique nucleotides in the 5' regulatory region, or a less specific region, e.g., especially in the 3' coding region, and the stringency of the hybridization or amplification (maximal, high, intermediate, or low) will determine whether the probe identifies only naturally occurring sequences encoding HRM, alleles, or related sequences.

10 Probes may also be used for the detection of related sequences, and should preferably contain at least 50% of the nucleotides from any of the HRM encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and derived from the nucleotide sequence of SEQ ID Nos:11-20 or from genomic sequence including promoter, enhancer elements, and introns of the naturally occurring HRM.

15 Means for producing specific hybridization probes for DNAs encoding HRM include the cloning of nucleic acid sequences encoding HRM or HRM derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, commercially available, and may be used to synthesize RNA probes *in vitro* by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be 20 labeled by a variety of reporter groups, for example, radionuclides such as 32P or 35S, or enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

25 Polynucleotide sequences encoding HRM may be used for the diagnosis of conditions, disorders, or diseases which are associated with either increased or decreased expression of HRM. Examples of such conditions or diseases include adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and cancers of the adrenal gland, bladder, bone, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, bone marrow, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; and immune disorders such as AIDS, 30 Addison's disease, adult respiratory distress syndrome, allergies, anemia, asthma, atherosclerosis, bronchitis, cholecystitis, Crohn's disease, ulcerative colitis, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, atrophic gastritis, glomerulonephritis, gout,

Graves' disease, hypereosinophilia, irritable bowel syndrome, lupus erythematosus, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, rheumatoid arthritis, scleroderma, Sjögren's syndrome, and thyroiditis. The polynucleotide sequences encoding HRM may be used in 5 Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; or in dipstick, pin, ELISA-like assays or microarrays utilizing fluids or tissues from patient biopsies to detect altered HRM expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding HRM may be useful in 10 assays that detect activation or induction of various cancers, particularly those mentioned above. The nucleotide sequences encoding HRM may be labeled by standard methods, and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantitated and compared with a standard value. If the amount of signal in the 15 biopsied or extracted sample is significantly altered from that of a comparable control sample, the nucleotide sequences have hybridized with nucleotide sequences in the sample, and the presence of altered levels of nucleotide sequences encoding HRM in the sample indicates the presence of the associated disease. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or in monitoring 20 the treatment of an individual patient.

In order to provide a basis for the diagnosis of disease associated with expression of HRM, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, which encodes HRM, under conditions suitable for 25 hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with those from an experiment where a known amount of a substantially purified polynucleotide is used. Standard values obtained from normal samples may be compared with values obtained from samples from patients who are symptomatic for disease. Deviation between standard and subject values is used to establish 30 the presence of disease.

Once disease is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to evaluate whether the level of expression in the patient

begins to approximate that which is observed in the normal patient. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

- With respect to cancer, the presence of a relatively high amount of transcript in
- 5 biopsied tissue from an individual may indicate a predisposition for the development of the disease or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.
- 10 Additional diagnostic uses for oligonucleotides designed from the sequences encoding HRM may involve the use of PCR. Such oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably consist of two nucleotide sequences, one with sense orientation (5'->3') and another with antisense (3'<-5'), employed under optimized conditions for identification of a specific gene or condition. The
- 15 same two oligomers, nested sets of oligomers, or even a degenerate pool of oligomers may be employed under less stringent conditions for detection and/or quantitation of closely related DNA or RNA sequences.

Methods which may also be used to quantitate the expression of HRM include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and

20 standard curves onto which the experimental results are interpolated (Melby, P.C. et al. (1993) J. Immunol. Methods, 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 229-236). The speed of quantitation of multiple samples may be accelerated by running the assay in an ELISA-like format where the oligomer of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

25 In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as targets in a microarray. The microarray can be used to monitor the expression level of large numbers of genes simultaneously (to produce a transcript image), and to identify genetic variants, mutations and polymorphisms. This information may be used to determine gene function, understanding the

30 genetic basis of disease, diagnosing disease, and in developing and in monitoring the activities of therapeutic agents.

In one embodiment, the microarray is prepared and used according to the methods

described in PCT application WO95/11995 (Chee et al.), Lockhart, D. J. et al. (1996; *Nat. Biotech.* 14: 1675-1680) and Schena, M. et al. (1996; *Proc. Natl. Acad. Sci.* 93: 10614-10619), all of which are incorporated herein in their entirety by reference.

The microarray is preferably composed of a large number of unique, single-stranded 5 nucleic acid sequences, usually either synthetic antisense oligonucleotides or fragments of cDNAs, fixed to a solid support. The oligonucleotides are preferably about 6-60 nucleotides in length, more preferably 15-30 nucleotides in length, and most preferably about 20-25 nucleotides in length. For a certain type of microarray, it may be preferable to use oligonucleotides which are only 7-10 nucleotides in length. The microarray may contain 10 oligonucleotides which cover the known 5', or 3', sequence, or contain sequential oligonucleotides which cover the full length sequence; or unique oligonucleotides selected from particular areas along the length of the sequence. Polynucleotides used in the microarray may be oligonucleotides that are specific to a gene or genes of interest in which at least a fragment of the sequence is known or that are specific to one or more unidentified 15 cDNAs which are common to a particular cell or tissue type or to a normal, developmental, or disease state. In certain situations it may be appropriate to use pairs of oligonucleotides on a microarray. The "pairs" will be identical, except for one nucleotide which preferably is located in the center of the sequence. The second oligonucleotide in the pair (mismatched by one) serves as a control. The number of oligonucleotide pairs may range from 2 to one 20 million.

In order to produce oligonucleotides to a known sequence for a microarray, the gene of interest is examined using a computer algorithm which starts at the 5' or more preferably at the 3' end of the nucleotide sequence. The algorithm identifies oligomers of defined length that are unique to the gene, have a GC content within a range suitable for hybridization, and 25 lack predicted secondary structure that may interfere with hybridization. In one aspect, the oligomers are synthesized at designated areas on a substrate using a light-directed chemical process. The substrate may be paper, nylon or other type of membrane, filter, chip, glass slide, or any other suitable solid support.

In another aspect, the oligonucleotides may be synthesized on the surface of the 30 substrate by using a chemical coupling procedure and an ink jet application apparatus, as described in PCT application WO95/251116 (Baldeschweiler et al.) which is incorporated herein in its entirety by reference. In another aspect, a "gridded" array analogous to a dot or

slot blot (HYBRIDOT apparatus, Life Technologies) may be used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. In yet another aspect, an array may be produced by hand or using available devices, materials, and machines (including Brinkmann 5 multichannel pipettors or robotic instruments) and may contain 8, 24, 96, 384, 1536 or 6144 oligonucleotides, or any other multiple from 2 to one million which lends itself to the efficient use of commercially available instrumentation.

In order to conduct sample analysis using the microarrays, polynucleotides are extracted from a biological sample. The biological samples may be obtained from any bodily 10 fluid (blood, urine, saliva, phlegm, gastric juices, etc.), cultured cells, biopsies, or other tissue preparations. To produce probes, the polynucleotides extracted from the sample are used to produce nucleic acid sequences which are complementary to the nucleic acids on the microarray. If the microarray consists of cDNAs, antisense RNAs (aRNA) are appropriate probes. Therefore, in one aspect, mRNA is used to produce cDNA which, in turn and in the 15 presence of fluorescent nucleotides, is used to produce fragment or oligonucleotide aRNA probes. These fluorescently labeled probes are incubated with the microarray so that the probe sequences hybridize to the cDNA oligonucleotides of the microarray. In another aspect, complementary nucleic acid sequences are used as probes and can also include polynucleotides, fragments, complementary, or antisense sequences produced using 20 restriction enzymes, PCR technologies, and Oligolabelling or TransProbe kits (Amersham Pharmacia) well known in the area of hybridization technology.

Incubation conditions are adjusted so that hybridization occurs with precise complementary matches or with various degrees of less complementarity. After removal of nonhybridized probes, a scanner is used to determine the levels and patterns of fluorescence. 25 The scanned images are examined to determine degree of complementarity and the relative abundance of each oligonucleotide sequence on the microarray. A detection system may be used to measure the absence, presence, and amount of hybridization for all of the distinct sequences simultaneously. This data may be used for large scale correlation studies or functional analysis of the sequences, mutations, variants, or polymorphisms among samples 30 (Heller, R.A. et al., (1997) Proc. Natl. Acad. Sci. 94:2150-55).

In another embodiment of the invention, the nucleic acid sequences which encode HRM may also be used to generate hybridization probes which are useful for mapping the

naturally occurring genomic sequence. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome or to artificial chromosome constructions, such as human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions or single chromosome

- 5 cDNA libraries as reviewed in Price, C.M. (1993; *Blood Rev.* 7:127-134) and Trask, B.J. (1991; *Trends Genet.* 7:149-154).

Fluorescent in situ hybridization (FISH as described in Verma et al. (1988) Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York NY) may be correlated with other physical chromosome mapping techniques and genetic map data.

- 10 Examples of genetic map data can be found in various scientific journals or at Online Mendelian Inheritance in Man (OMIM). Correlation between the location of the gene encoding HRM on a physical chromosomal map and a specific disease, or predisposition to a specific disease, may help delimit the region of DNA associated with that genetic disease. The nucleotide sequences of the subject invention may be used to detect differences in gene sequences between normal, carrier, or affected individuals.
- 15

In situ hybridization of chromosomal preparations and physical mapping techniques such as linkage analysis using established chromosomal markers may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of a 20 particular human chromosome is not known. New sequences can be assigned to chromosomal arms, or parts thereof, by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, for example, AT to 11q22-23 (Gatti, R.A. et al. (1988) *Nature* 336:577-580), any sequences mapping to that area may represent associated or 25 regulatory genes for further investigation. The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc. among normal, carrier, or affected individuals.

In another embodiment of the invention, HRM, its catalytic or immunogenic 30 fragments or oligopeptides thereof, can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The

formation of binding complexes, between HRM and the agent being tested, may be measured.

Another technique for drug screening which may be used provides for high throughput screening of compounds having suitable binding affinity to the protein of interest as described in published PCT application WO84/03564. In this method, large numbers of different small

5 test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The test compounds are reacted with HRM, or fragments thereof, and washed.

Bound HRM is then detected by methods well known in the art. Purified HRM can also be coated directly onto plates for use in the aforementioned drug screening techniques.

Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize
10 it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding HRM specifically compete with a test compound for binding HRM. In this manner, the antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with HRM.

15 In additional embodiments, the nucleotide sequences which encode HRM may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

The examples below are provided to illustrate the subject invention and are not
20 included for the purpose of limiting the invention.

EXAMPLES

For purposes of example, the preparation and sequencing of the LNODNOT03 cDNA library, from which Incyte Clones were isolated, is described. Preparation and sequencing of cDNAs in libraries in the LIFESEQ database (Incyte Pharmaceuticals, Palo Alto CA) have
25 varied over time, and the gradual changes involved use of kits, plasmids, and machinery available at the particular time the library was made and analyzed.

I LNODNOT03 cDNA Library Construction

The LNODNOT03 cDNA library was constructed from microscopically normal lymph node tissue excised from a 67-year-old Caucasian male with lung cancer during a
30 segmental lung resection. This nontumorous tissue was associated with an invasive grade 3 squamous cell carcinoma of the lung. The patient history included hemangioma and tobacco use. The patient was taking DOXYCYCLINE, a tetracycline, to treat an infection.

- The frozen tissue was homogenized and lysed using a Brinkmann Homogenizer Polytron PT-3000 (Brinkmann Instruments, Westbury NJ) in guanidinium isothiocyanate solution. The lysate was centrifuged over a 5.7 M CsCl cushion using a Beckman SW28 rotor in a Beckman L8-70M Ultracentrifuge (Beckman Coulter Instruments, Fullerton CA) 5 for 18 hours at 25,000 rpm at ambient temperature. The RNA was extracted with acid phenol pH 4.7, precipitated using 0.3 M sodium acetate and 2.5 volumes of ethanol, resuspended in RNase-free water, and treated with DNase at 37°C. Extraction and precipitation were repeated as before. The mRNA was isolated with the OLIGOTEX kit (QIAGEN, Inc., Chatsworth CA) and used to construct the cDNA library.
- 10 The mRNA was handled according to the recommended protocols in the SUPERSCRIPT Plasmid System for cDNA synthesis and plasmid cloning (Life Technologies). The cDNAs were fractionated on a SEPHAROSE CL4B column (Amersham Pharmacia), and those cDNAs exceeding 400 bp were ligated into pINCY 1. The plasmid pINCY (Incyte Pharmaceuticals) was subsequently transformed into DH5 α competent cells 15 (Life Technologies).

II Isolation and Sequencing of cDNA Clones

- Plasmid DNA was released from the cells and purified using the REAL Prep 96 plasmid kit (QIAGEN, Inc.). This kit enabled the simultaneous purification of 96 samples in a 96-well block using multi-channel reagent dispensers. The recommended protocol was 20 employed except for the following changes: 1) the bacteria were cultured in 1 ml of sterile Terrific Broth (Life Technologies) with carbenicillin at 25 mg/L and glycerol at 0.4%; 2) after inoculation, the cultures were incubated for 19 hours and at the end of incubation, the cells were lysed with 0.3 ml of lysis buffer; and 3) following isopropanol precipitation, the plasmid DNA pellet was resuspended in 0.1 ml of distilled water. After the last step in the protocol, 25 samples were transferred to a 96-well block for storage at 4°C.

The cDNAs were sequenced by the method of Sanger et al. (1975, J. Mol. Biol. 94:441f), using a Micro Lab 2200 (Hamilton, Reno NV) in combination with PTC200 from MJ Research, and ABI 377 DNA sequencing systems (Perkin Elmer); and the reading frame was determined.

30 III Homology Searching of cDNA Clones and Their Deduced Proteins

The nucleotide sequences and/or amino acid sequences of the Sequence Listing were used to query sequences in the GenBank, SwissProt, BLOCKS, and Pima II databases. These

databases, which contain previously identified and annotated sequences, were searched for regions of homology using BLAST, which stands for Basic Local Alignment Search Tool (Altschul, S.F. (1993) J. Mol. Evol 36:290-300; Altschul, et al. (1990) J. Mol. Biol. 215:403-410).

5 BLAST produced alignments of both nucleotide and amino acid sequences to determine sequence similarity. Because of the local nature of the alignments, BLAST was especially useful in determining exact matches or in identifying homologs which may be of prokaryotic (bacterial) or eukaryotic (animal, fungal, or plant) origin. Other algorithms such as the one described in Smith, T. et al. (1992, Protein Engineering 5:35-51), incorporated
10 herein by reference, could have been used when dealing with primary sequence patterns and secondary structure gap penalties. The sequences disclosed in this application have lengths of at least 49 nucleotides, and no more than 12% uncalled bases (where N is recorded rather than A, C, G, or T).

15 The BLAST approach searched for matches between a query sequence and a database sequence. BLAST evaluated the statistical significance of any matches found, and reported only those matches that satisfy the user-selected threshold of significance. In this application, threshold was set at 10^{-25} for nucleotides and 10^{-14} for peptides.

20 Incyte nucleotide sequences were searched against the GenBank databases for primate (pri), rodent (rod), and other mammalian sequences (mam); and deduced amino acid sequences from the same clones were then searched against GenBank functional protein databases, mammalian (mamp), vertebrate (vrtp), and eukaryote (eukp) for homology.

IV Northern Analysis

25 Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound (Sambrook et al., *supra*).

30 Analogous computer techniques use BLAST to search for identical or related molecules in nucleotide databases such as GenBank or the LIFESEQ database (Incyte Pharmaceuticals). This analysis is much faster than multiple, membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or homologous.

The basis of the search is the product score which is defined as:

$$\frac{\% \text{ sequence identity} \times \% \text{ maximum BLAST score}}{100}$$

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within a 1-2% error; and at 70, the match will be exact. Homologous molecules are usually identified by selecting those which show product scores between 15 and 40, although 5 lower scores may identify related molecules.

The results of northern analysis are reported as a list of libraries in which the transcript encoding HRM occurs. Abundance and percent abundance are also reported. Abundance directly reflects the number of times a particular transcript is represented in a cDNA library, and percent abundance is abundance divided by the total number of sequences 10 examined in the cDNA library.

V Extension of HRM Encoding Polynucleotides

The nucleic acid sequence of an Incyte Clone disclosed in the Sequence Listing was used to design oligonucleotide primers for extending a partial nucleotide sequence to full length. One primer was synthesized to initiate extension in the antisense direction, and the 15 other was synthesized to extend sequence in the sense direction. Primers were used to facilitate the extension of the known sequence "outward" generating amplicons containing new, unknown nucleotide sequence for the region of interest. The initial primers were designed from the cDNA using OLIGO 4.06 (National Biosciences), or another appropriate program, to be about 22 to about 30 nucleotides in length, to have a GC content of 50% or 20 more, and to anneal to the target sequence at temperatures of about 68° to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries (Life Technologies) were used to extend the sequence. If more than one extension is necessary or desired, additional sets of primers are designed to 25 further extend the known region.

High fidelity amplification was obtained by following the instructions for the XL-PCR kit (Perkin Elmer) and thoroughly mixing the enzyme and reaction mix. Beginning with 40 pmol of each primer and the recommended concentrations of all other components of the kit, PCR was performed using the PTC200 (MJ Research) and the following parameters: Step 1, 30 94° C for 1 min (initial denaturation); Step 2, 65° C for 1 min; Step 3, 68° C for 6 min; Step 4, 94° C for 15 sec; Step 5, 65° C for 1 min; Step 6, 68° C for 7 min; Step 7, for 15 additional cycles; Step 8, 94° C for 15 sec; Step 9, 65° C for 1 min; Step 10, 68° C for 7:15 min; Step

11, Repeat step 8-10 for 12 cycles; Step 12, 72° C for 8 min; and Step 13, hold at 4° C.

A 5-10 μ l aliquot of the reaction mixture was analyzed by electrophoresis on a low concentration (about 0.6-0.8%) agarose mini-gel to determine which reactions were successful in extending the sequence. Bands thought to contain the largest products were 5 excised from the gel, purified using QIAQUICK kit (QIAGEN Inc.), and trimmed of overhangs using Klenow enzyme to facilitate religation and cloning.

After ethanol precipitation, the products were redissolved in 13 μ l of ligation buffer, 1 μ l T4-DNA ligase (15 units) and 1 μ l T4 polynucleotide kinase were added, and the mixture was incubated at room temperature for 2-3 hours or overnight at 16° C. Competent *E. coli* 10 cells (in 40 μ l of appropriate media) were transformed with 3 μ l of ligation mixture and cultured in 80 μ l of SOC medium (Sambrook et al., supra). After incubation for one hour at 37° C, the *E. coli* mixture was plated on Luria Bertani (LB)-agar (Sambrook et al., supra) containing 2x Carb. The following day, several colonies were randomly picked from each plate and cultured in 150 μ l of liquid LB/2x Carb medium placed in an individual well of an 15 appropriate, commercially-available, sterile 96-well microtiter plate. The following day, 5 μ l of each overnight culture was transferred into a non-sterile 96-well plate and after dilution 1:10 with water, 5 μ l of each sample was transferred into a PCR array.

For PCR amplification, 18 μ l of concentrated PCR reaction mix (3.3x) containing 4 units of rTth DNA polymerase, a vector primer, and one or both of the gene specific primers 20 used for the extension reaction were added to each well. Amplification was performed using the following conditions: Step 1, 94° C for 60 sec; Step 2, 94° C for 20 sec; Step 3, 55° C for 30 sec; Step 4, 72° C for 90 sec; Step 5, Repeat steps 2-4 for an additional 29 cycles; Step 6, 72° C for 180 sec; and Step 7, hold at 4° C.

Aliquots of the PCR reactions were run on agarose gels together with molecular 25 weight markers. The sizes of the PCR products were compared to the original partial cDNAs, and appropriate clones were selected, ligated into plasmid, and sequenced.

In like manner, the nucleotide sequence of SEQ ID NOS:11-20 are used to obtain 5' regulatory sequences using the procedure above, oligonucleotides designed for 5' extension, and an appropriate genomic library.

30 **VI Labeling and Use of Individual Hybridization Probes**

Hybridization probes derived from SEQ ID NOS:11-20 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of

about 20 base-pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 (National Biosciences), labeled by combining 50 pmol of each oligomer and 250 μ Ci of [γ - 32 P] adenosine triphosphate (Amersham Pharmacia) and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified with SEPHADEX G-25 superfine resin column (Amersham Pharmacia). A aliquot containing 10^7 counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases (Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II; DuPont NEN).

10 The DNA from each digest is fractionated on a 0.7 percent agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under increasingly stringent conditions up to 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. After XOMAT AR film (Eastman 15 Kodak, Rochester NY) is exposed to the blots in a Phosphoimager cassette (Molecular Dynamics, Sunnyvale CA) for several hours, hybridization patterns are compared visually.

VII Microarrays

To produce oligonucleotides for a microarray, SEQ ID NOS: 11-20 are examined using a computer algorithm which starts at the 3' end of the nucleotide sequence. The algorithm 20 identified oligomers of defined length that are unique to the gene, have a GC content within a range suitable for hybridization, and lack predicted secondary structure that would interfere with hybridization. The algorithm identifies approximately 20 sequence-specific oligonucleotides of 20 nucleotides in length (20-mers). A matched set of oligonucleotides are created in which one nucleotide in the center of each sequence is altered. This process is 25 repeated for each gene in the microarray, and double sets of twenty 20 mers are synthesized and arranged on the surface of the silicon chip using a light-directed chemical process (Chee, M. et al., PCT/WO95/11995, incorporated herein by reference).

In the alternative, a chemical coupling procedure and an ink jet device are used to 30 synthesize oligomers on the surface of a substrate (Baldeschweiler, J.D. et al., PCT/WO95/25116, incorporated herein by reference). In another alternative, a "gridded" array analogous to a dot (or slot) blot is used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV,

mechanical or chemical bonding procedures. A typical array may be produced by hand or using available materials and machines and contain grids of 8 dots, 24 dots, 96 dots, 384 dots, 1536 dots or 6144 dots. After hybridization, the microarray is washed to remove nonhybridized probes, and a scanner is used to determine the levels and patterns of 5 fluorescence. The scanned image is examined to determine degree of complementarity and the relative abundance/expression level of each oligonucleotide sequence in the microarray.

VIII Complementary Polynucleotides

Sequence complementary to the sequence encoding HRM, or any part thereof, is used to detect, decrease or inhibit expression of naturally occurring HRM. Although use of 10 oligonucleotides comprising from about 15 to about 30 base-pairs is described, essentially the same procedure is used with smaller or larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software and the coding sequence of HRM, SEQ ID NOs:11-20. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding 15 sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the transcript encoding HRM.

IX Expression of HRM

Expression of HRM is accomplished by subcloning the cDNAs into appropriate vectors and transforming the vectors into host cells. In this case, the cloning vector is also 20 used to express HRM in *E. coli*. Upstream of the cloning site, this vector contains a promoter for β -galactosidase, followed by sequence containing the amino-terminal Met, and the subsequent seven residues of β -galactosidase. Immediately following these eight residues is a bacteriophage promoter useful for transcription and a linker containing a number of unique restriction sites.

25 Induction of an isolated, transformed bacterial strain with IPTG using standard methods produces a fusion protein which consists of the first eight residues of β -galactosidase, about 5 to 15 residues of linker, and the full length protein. The signal residues direct the secretion of HRM into the bacterial growth media which can be used directly in the following assay for activity.

X Demonstration of HRM Activity

HRM can be expressed in a mammalian cell line such as DLD-1 or HCT116 (ATCC) 30 by transforming the cells with a eukaryotic expression vector encoding HRM. Eukaryotic

expression vectors are commercially available and the techniques to introduce them into cells are well known to those skilled in the art. The effect of HRM on cell morphology may be visualized by microscopy; the effect on cell growth may be determined by measuring cell doubling-time; and the effect on tumorigenicity may be assessed by the ability of transformed cells to grow in a soft agar growth assay (Groden, J. et al. (1995) *Cancer Res.* 55:1531-1539).

5 **XI Production of HRM Specific Antibodies**

HRM that is substantially purified using PAGE electrophoresis (Sambrook, *supra*), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols. The amino acid sequence deduced from SEQ ID NOs:11-20 is analyzed 10 using LASERGENE software (DNASTAR Inc) to determine regions of high immunogenicity and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions, is described by Ausubel et al. (*supra*), and others.

Typically, the oligopeptides are 15 residues in length, synthesized using an Applied 15 Biosystems Peptide Synthesizer Model 431A using fmoc-chemistry, and coupled to keyhole limpet hemocyanin (KLH, Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS; Ausubel et al., *supra*). Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. The resulting 20 antisera are tested for antipeptide activity, for example, by binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio iodinated, goat anti-rabbit IgG.

25 **XII Purification of Naturally Occurring HRM Using Specific Antibodies**

Naturally occurring or recombinant HRM is substantially purified by immunoaffinity chromatography using antibodies specific for HRM. An immunoaffinity column is 25 constructed by covalently coupling HRM antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing HRM is passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of HRM (e.g., high ionic 30 strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/protein binding (eg, a buffer of pH 2-3 or a high concentration of a chaotrope, such as urea or thiocyanate ion), and HRM is collected.

XIII Identification of Molecules Which Interact with HRM

HRM or biologically active fragments thereof are labeled with ^{125}I Bolton-Hunter reagent (Bolton et al. (1973) Biochem. J. 133: 529). Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled HRM, washed and any wells with labeled HRM complex are assayed. Data obtained using different concentrations of HRM are used to calculate values for the number, affinity, and association of HRM with the candidate molecules.

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

What is claimed is:

1. A substantially purified human regulatory molecule (HRM) comprising a polypeptide having an amino acid sequence selected from the group consisting of: SEQ ID NOs:1-10.
- 5 2. An isolated and purified polynucleotide sequence having a nucleic acid sequence encoding the human regulatory molecule of claim 1.
3. An isolated and purified polynucleotide sequence which hybridizes under stringent conditions to the polynucleotide sequence of claim 2.
4. A composition comprising the polynucleotide sequence of claim 2.
- 10 5. An isolated and purified polynucleotide sequence having a nucleic acid sequence selected from the group consisting of: SEQ ID NOs:11-20.
6. A microarray containing at least a fragment of at least one of the polynucleotides encoding a polypeptide having an amino acid sequence having the sequence selected from the group consisting of SEQ ID NOs:1-10.
- 15 7. A microarray containing at least a fragment of at least one of the polynucleotides having a nucleic acid selected from the group consisting of: SEQ ID NOs:11-20.
8. An isolated and purified polynucleotide having a nucleic acid sequence which is complementary to the nucleic acid sequence of the polynucleotide of claim 5.
- 20 9. A composition comprising the polynucleotide of claim 5.
10. An expression vector containing the polynucleotide of claim 2.
11. A host cell containing the vector of claim 10.
12. A method for producing a polypeptide encoding a human regulatory molecule, the method comprising the steps of:
 - 25 a) culturing the host cell of claim 11 under conditions suitable for the expression of the polypeptide; and
 - b) recovering the polypeptide from the host cell culture.
13. A pharmaceutical composition comprising a substantially purified human regulatory molecule of claim 1 in conjunction with a suitable pharmaceutical carrier.
- 30 14. A purified antibody which binds specifically to the human regulatory molecule of claim 1.
15. A purified agonist which modulates the activity of the human regulatory

molecule of claim 1.

16. A purified antagonist which decreases the effect of the human regulatory molecule of claim 1.

17. A method for stimulating cell proliferation comprising administering to a cell 5 an effective amount of the human regulatory molecule of claim 1.

18. A method for preventing a cancer comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 13.

19. A method for treating or preventing a cancer comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 16.

10 20. A method for treating or preventing an immune response comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 16.

21. A method for detecting a polynucleotide encoding a human regulatory molecule in a biological sample, the method comprising the steps of:

15 a) hybridizing the polynucleotide of claim 8 to nucleic acid material of a biological sample, thereby forming a hybridization complex; and
b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of a polynucleotide encoding a human regulatory molecule in the biological sample.

20 22. A method for detecting expression levels of polynucleotides encoding a human regulatory molecule in a biological sample, the method comprising the steps of:

a) hybridizing the microarray of claim 6 to labeled complementary polynucleotides derived from the biological sample, thereby forming hybridization complexes; and
25 b) determining expression of polynucleotides encoding a human regulatory molecule in the biological sample by identifying the presence of the hybridization complexes.

23. A method for detecting expression levels of polynucleotides encoding a human regulatory molecule in a biological sample, the method comprising the steps of:

30 a) hybridizing the microarray of claim 7 to labeled complementary polynucleotides derived from the biological sample, thereby forming hybridization complexes; and

b) determining expression of polynucleotides encoding a human regulatory molecule in the biological sample by identifying the presence of the hybridization complexes.

24. The method of claim 22, wherein before hybridization, the nucleic acid
5 material of the biological sample is amplified and labeled by the polymerase chain reaction.

WO 99/15658

SEQUENCE LISTING

<110> INCYTE PHARMACEUTICALS, INC.
LAL, Preeti
HILLMAN, Jennifer L.
BANDMAN, Olga
SHAH, Purvi
AU-YOUNG, Janice
YUE, Henry
GUEGLER, Karl J.

<120> HUMAN REGULATORY MOLECULES

<130> PF-0356 PCT

1900 22

<150> US 08/933,750

<151> 1997-09-23

<160> 20

<170> PERL Program

<210> 1

<211> 456

<212> PRT

220 -

~~223~~ 223 009476

<400> 1	Met Lys Ile Glu Glu Val Lys Ser Thr Thr Lys Thr Gln Arg Ile	15
1	5	10
Ala Ser His Ser His Val Lys Gly Leu Gly Leu Asp Glu Ser Gly	30	
20	25	
Leu Ala Lys Gin Ala Ala Ser Gly Leu Val Gly Gln Glu Asn Ala	45	
35	40	
Arg Glu Ala Cys Gly Val Ile Val Glu Leu Ile Glu Ser Lys Lys	60	
50	55	
Met Ala Gly Arg Ala Val Leu Leu Ala Gly Pro Pro Gly Thr Gly	75	
65	70	
Lys Thr Ala Leu Ala Ieu Ala Ile Ala Gln Glu Leu Gly Ser Lys	90	
80	85	
Val Pro Phe Cys Pro Met Val Gly Ser Glu Val Tyr Ser Thr Glu	105	
95	100	
Ile Lys Lys Thr Glu Val Leu Met Glu Asn Phe Arg Arg Ala Ile	120	
110	115	
Gly Leu Arg Ile Lys Glu Thr Lys Glu Val Tyr Glu Gly Glu Val	135	
125	130	
Thr Glu Leu Thr Pro Cys Glu Thr Glu Asn Pro Met Gly Gly Tyr	150	
140	145	
Gly Lys Thr Ile Ser His Val Ile Ile Gly Leu Lys Thr Ala Lys	165	
155	160	
Gly Thr Lys Gin Leu Lys Leu Asp Pro Ser Ile Phe Glu Ser Leu	180	
170	175	
Gin Lys Glu Arg Val Glu Ala Gly Asp Val Ile Tyr Ile Glu Ala	195	
185	190	
Asn Ser Gly Ala Val Lys Arg Gln Gly Arg Cys Asp Thr Tyr Ala	210	
200	205	
Thr Glu Phe Asp Leu Glu Ala Glu Glu Tyr Val Pro Leu Pro Lys		

WO 99/15658

WO 99/15030 225
 Gly Asp Val His Lys Lys Lys Glu Ile Ile Gln Asp Val Thr Leu
 215 220 240
 His Asp Leu Asp Val Ala Asn Ala Arg Pro Gln Gly Gly Gln Asp
 230 235 255
 Ile Leu Ser Met Met Gly Gln Leu Met Lys Pro Lys Lys Thr Glu
 245 250 270
 Ile Thr Asp Lys Leu Arg Gly Glu Ile Asn Lys Val Val Asn Lys
 260 265 285
 Tyr Ile Asp Gln Gly Ile Ala Glu Leu Val Pro Gly Val Leu Phe
 275 280 300
 Val Asp Glu Val His Met Leu Asp Ile Glu Cys Phe Thr Tyr Leu
 290 295 315
 His Arg Ala Leu Glu Ser Ser Ile Ala PRO Ile Val Ile Phe Ala
 305 310 330
 His Arg Ala Leu Glu Ser Ser Ile Ala PRO Ile Val Ile Phe Ala
 320 325 345
 Ser Asn Arg Gly Asn Cys Val Ile Arg Gly Thr Glu Asp Ile Thr
 335 340 360
 Ser Pro His Gly Ile Pro Leu Asp Leu Leu Asp Arg Val Met Ile
 350 355 375
 Ile Arg Thr Met Leu Tyr Thr Pro Gln Glu Met Lys Gln Ile Ile
 365 370 390
 Lys Ile Arg Ala Gln Thr Glu Gly Ile Asn Ile Ser Glu Glu Ala
 380 385 405
 Leu Asn His Leu Gly Glu Ile Gly Thr Lys Thr Thr Leu Arg Tyr
 395 400 420
 Ser Val Gln Leu Leu Thr Pro Ala Asn Leu Leu Ala Lys Ile Asn
 410 415 435
 Gly Lys Asp Ser Ile Glu Lys Glu His Val Glu Glu Ile Ser Glu
 425 430 450
 Leu Phe Tyr Asp Ala Lys Ser Ser Ala Lys Ile Leu Ala Asp Gln
 440 445 465
 Gln Asp Lys Tyr Met Lys
 455

<210> 2
<211> 188
<212> PRT
<213> *Homo sapiens*

<220> -
<223> 077180

<400> 2	Met Ala Leu Ala Met Leu Val Leu Val Val Ser Pro Trp Ser Ala	15
1	5	10
Aia Arg Gly Val	Leu Arg Asn Tyr Trp Glu Arg Ieu Leu Arg Lys	30
20	25	
Leu Pro Gln Ser Arg	Pro Gly Phe Pro Ser Pro Pro Trp Gly Pro	45
35	40	
Ala Leu Ala Val Gln	Giy Pro Ala Met Phe Thr Glu Pro Ala Asn	60
50	55	
Asp Thr Ser Gly Ser	Lys Glu Asn Ser Ser Leu Leu Asp Ser Ile	75
65	70	
Phe Trp Met Ala Ala	Pro Lys Asn Arg Arg Thr Ile Glu Val Asn	90
80	85	
Arg Cys Arg Arg Arg	Asn Pro Gln Lys Leu Ile Lys Val Lys Asn	105
95	100	
Asn Ile Asp Val	Cys Pro Glu Cys Giy His Leu Lys Gln Lys His	120
110	115	
Val Leu Cys Ala	Tyr Cys Tyr Glu Lys Val Cys Lys Glu Thr Ala	135
125	130	
Glu Ile Arg Arg Gln	Ile Gly Lys Gln Glu Gly Pro Phe Lys	

WO 99/15658

140	145	150
Ala Pro Thr Ile Glu Thr Val Val Leu Tyr	Thr	Gly Glu Thr Pro
155	160	165
Ser Glu Gln Asp Gln Gly Lys Arg Ile	Ile	Glu Arg Asp Arg Lys
170	175	180
Arg Pro Ser Trp Phe Thr Gln Asn		
	185	

<210> 3
<211> 348
<212> PRT
<213> Homo sapiens

<220> -
<223> 118160CD1

<400> 3
Met Gly Gln Glu Glu Glu Leu Leu Arg Ile Ala Lys Lys Leu Glu
1 5 10 15
Lys Met Val Ala Arg Lys Asn Thr Glu Gly Ala Leu Asp Leu Leu
20 25 30
Lys Lys Leu His Ser Cys Gln Met Ser Ile Gln Leu Leu Gln Thr
35 40 45
Thr Arg Ile Gly Val Ala Val Asn Gly Val Arg Lys His Cys Ser
50 55 60
Asp Lys Glu Val Val Ser Leu Ala Lys Val Leu Ile Lys Asn Trp
65 70 75
Lys Arg Leu Leu Asp Ser Pro Gly Pro Pro Lys Gly Glu Lys Gly
80 85 90
Glu Glu Arg Glu Lys Ala Lys Lys Glu Lys Gly Leu Glu Cys
95 100 105
Ser Asp Trp Lys Pro Glu Ala Gly Leu Ser Pro Pro Arg Lys Lys
110 115 120
Arg Glu Asp Pro Lys Thr Arg Arg Asp Ser Val Asp Ser Lys Ser
125 130 135
Ser Ala Ser Ser Ser Pro Lys Arg Pro Ser Val Glu Arg Ser Asn
140 145 150
Ser Ser Lys Ser Lys Ala Glu Ser Pro Lys Thr Pro Ser Ser Pro
155 160 165
Leu Thr Pro Thr Phe Ala Ser Ser Met Cys Leu Leu Ala Pro Cys
170 175 180
Tyr Leu Thr Gly Asp Ser Val Arg Asp Lys Cys Val Glu Met Leu
185 190 195
Ser Ala Ala Leu Lys Ala Asp Asp Tyr Lys Asp Tyr Gly Val
200 205 210
Asn Cys Asp Lys Met Ala Ser Glu Ile Glu Asp His Ile Tyr Gln
215 220 225
Glu Leu Lys Ser Thr Asp Met Lys Tyr Arg Asn Arg Val Arg Ser
230 235 240
Arg Ile Ser Asn Leu Lys Asp Pro Arg Asn Pro Gly Leu Arg Arg
245 250 255
Asn Val Leu Ser Gly Ala Ile Ser Ala Gly Leu Ile Ala Lys Met
260 265 270
Thr Ala Glu Glu Met Ala Ser Asp Glu Leu Arg Glu Leu Arg Asn
275 280 285
Ala Met Thr Gin Glu Ala Ile Arg Glu His Gln Met Ala Lys Thr
290 295 300
Gly Gly Thr Thr Thr Asp Leu Phe Gln Cys Ser Lys Cys Lys Lys
305 310 315
Lys Asn Cys Thr Tyr Asn Gln Val Gln Thr Arg Ser Ala Asp Glu
320 325 330
Pro Met Thr Thr Phe Val Leu Cys Asn Glu Cys Gly Asn Arg Trp

Lys Phe Cys

<210> 4
 <211> 261
 <212> PRT
 <213> Homo sapiens

<220> -
 <223> 933353

<400> 4
 Met Ala Ala Thr Ala Leu Leu Glu Ala Gly Leu Ala Arg Val Leu
 5 10 15
 Phe Tyr Pro Thr Leu Leu Tyr Thr Leu Phe Arg Gly Lys Val Pro
 20 25 30
 Gly Arg Ala His Arg Asp Trp Tyr His Arg Ile Asp Pro Thr Val
 35 40 45
 Leu Leu Gly Ala Leu Pro Leu Arg Ser Leu Thr Arg Gln Leu Val
 50 55 60
 Gln Asp Glu Asn Val Arg Gly Val Ile Thr Met Asn Glu Gln Tyr
 65 70 75
 Glu Thr Arg Phe Leu Cys Asn Ser Ser Gln Glu Trp Lys Arg Leu
 80 85 90
 Gly Val Glu Gln Leu Arg Leu Ser Thr Val Asp Met Thr Gly Ile
 95 100 105
 Pro Thr Leu Asp Asn Leu Gln Lys Gly Val Gln Phe Ala Leu Lys
 110 115 120
 Tyr Gln Ser Leu Gly Gln Cys Val Tyr Val His Cys Lys Ala Gly
 125 130 135
 Arg Ser Arg Ser Ala Thr Met Val Ala Ala Tyr Leu Ile Gln Val
 140 145 150
 His Lys Trp Ser Pro Glu Glu Ala Val Arg Ala Ile Ala Lys Ile
 155 160 165
 Arg Ser Tyr Ile His Ile Arg Pro Gln Gln Leu Asp Val Leu Lys
 170 175 180
 Glu Phe His Lys Gln Ile Thr Ala Arg Ala Thr Lys Asp Gln Thr
 185 190 195
 Phe Val Ile Ser Lys Thr
 200

<210> 5
 <211> 431
 <212> PRT
 <213> Homo sapiens

<220>
 <221> unsure
 <222> 218
 <223> unknown, or other

<220> -
 <223> 1568361

<400> 5
 Met Ser Ser Val Glu Glu Asp Asp Tyr Asp Thr Leu Thr Asp Ile
 1 5 10 15
 Asp Ser Asp Lys Asn Val Ile Arg Thr Lys Gln Tyr Leu Tyr Val
 20 25 30

WO 99/15658

Ala Asp Leu Ala Arg Lys Asp Lys Arg Val Leu Arg Lys Lys Tyr
 35 40 45
 Gln Ile Tyr Phe Trp Asn Ile Ala Thr Ile Ala Val Phe Tyr Ala
 50 55 60
 Leu Pro Val Val Gln Leu Val Ile Thr Tyr Gln Thr Val Val Asn
 65 70 75
 Val Thr Gly Asn Gln Asp Ile Cys Tyr Tyr Asn Phe Leu Cys Ala
 80 85 90
 His Pro Leu Gly Asn Leu Ser Ala Phe Asn Asn Ile Leu Ser Asn
 95 100 105
 Leu Gly Tyr Ile Leu Leu Gly Leu Leu Phe Leu Leu Ile Ile Leu
 110 115 120
 Gln Arg Glu Ile Asn His Asn Arg Ala Leu Leu Arg Asn Asp Leu
 125 130 135
 Cys Ala Leu Glu Cys Gly Ile Pro Lys His Phe Gly Leu Phe Tyr
 140 145 150
 Ala Met Gly Thr Ala Leu Met Met Glu Gly Leu Leu Ser Ala Cys
 155 160 165
 Tyr His Val Cys Pro Asn Tyr Thr Asn Phe Gln Phe Asp Thr Ser
 170 175 180
 Phe Met Tyr Met Ile Ala Gly Leu Cys Met Leu Lys Leu Tyr Gln
 185 190 195
 Lys Arg His Pro Asp Ile Asn Ala Ser Ala Tyr Ser Ala Tyr Ala
 200 205 210
 Cys Leu Ala Ile Val Ile Phe Xaa Ser Val Leu Gly Val Val Phe
 215 220 225
 Gly Lys Gly Asn Thr Ala Phe Trp Ile Val Phe Ser Ile Ile His
 230 235 240
 Ile Ile Ala Thr Leu Leu Leu Ser Thr Gln Leu Tyr Tyr Met Gly
 245 250 255
 Arg Trp Lys Leu Asp Ser Gly Ile Phe Arg Arg Ile Leu His Val
 260 265 270
 Leu Tyr Thr Asp Cys Ile Arg Gln Cys Ser Gly Pro Leu Tyr Val
 275 280 285
 Asp Arg Met Val Leu Leu Val Met Gly Asn Val Ile Asn Trp Ser
 290 295 300
 Leu Ala Ala Tyr Gly Leu Ile Met Arg Pro Asn Asp Phe Ala Ser
 305 310 315
 Tyr Leu Leu Ala Ile Gly Ile Cys Asn Leu Leu Tyr Phe Ala
 320 325 330
 Phe Tyr Ile Ile Met Lys Leu Arg Ser Gly Glu Arg Ile Lys Leu
 335 340 345
 Ile Pro Leu Leu Cys Ile Val Cys Thr Ser Val Val Trp Gly Phe
 350 355 360
 Ala Leu Phe Phe Phe Phe Gln Gly Leu Ser Thr Trp Gln Lys Thr
 365 370 375
 Pro Ala Glu Ser Arg Glu His Asn Arg Asp Cys Ile Leu Leu Asp
 380 385 390
 Phe Phe Asp Asp His Asp Ile Trp His Phe Leu Ser Ser Ile Ala
 395 400 405
 Met Phe Gly Ser Phe Leu Val Leu Leu Thr Leu Asp Asp Asp Leu
 410 415 420
 Asp Thr Val Gln Arg Asp Lys Ile Tyr Val Phe
 425 430

<210> 6
 <211> 419
 <212> PRT
 <213> Homo sapiens

<220> -
 <223> 1600438

WO 99/15658

<400> 6
 Met Asn Lys His Gln Lys Pro Val Leu Thr Gly Gln Arg Phe Lys
 1 5 15
 Thr Arg Lys Arg Asp Glu Lys Glu Lys Phe Glu Pro Thr Val Phe
 20 30
 Arg Asp Thr Leu Val Gln Gly Leu Asn Glu Ala Gly Asp Asp Leu
 35 45
 Glu Ala Val Ala Lys Phe Leu Asp Ser Thr Gly Ser Arg Ieu Asp
 50 60
 Tyr Arg Arg Tyr Ala Asp Thr Leu Phe Asp Ile Leu Val Ala Gly
 65 75
 Ser Met Leu Ala Pro Gly Gly Thr Arg Ile Asp Asp Gly Asp Lys
 80 90
 Thr Lys Met Thr Asn His Cys Val Phe Ser Ala Asn Glu Asp His
 95 105
 Glu Thr Ile Arg Asn Tyr Ala Gln Val Phe Asn Lys Leu Ile Arg
 110 120
 Arg Tyr Lys Tyr Leu Glu Lys Ala Phe Glu Asp Glu Met Lys Lys
 125 135
 Leu Leu Leu Phe Leu Lys Ala Phe Ser Glu Thr Glu Gln Thr Lys
 140 150
 Leu Ala Met Leu Ser Gly Ile Leu Leu Gly Asn Gly Thr Leu Pro
 155 165
 Ala Thr Ile Leu Thr Ser Leu Phe Thr Asp Ser Leu Val Lys Glu
 170 180
 Gly Ile Ala Ala Ser Phe Ala Val Lys Leu Phe Lys Ala Trp Met
 185 195
 Ala Glu Lys Asp Ala Asn Ser Val Thr Ser Ser Leu Arg Lys Ala
 200 210
 Asn Leu Asp Lys Arg Leu Leu Glu Leu Phe Pro Val Asn Arg Gln
 215 225
 Ser Val Asp His Phe Ala Lys Tyr Phe Thr Asp Ala Gly Leu Lys
 230 240
 Glu Leu Ser Asp Phe Leu Arg Val Gln Gln Ser Leu Gly Thr Arg
 245 255
 Lys Glu Leu Gln Lys Glu Leu Gln Glu Arg Leu Ser Gln Glu Cys
 260 270
 Pro Ile Lys Glu Val Val Leu Tyr Val Lys Glu Glu Met Lys Arg
 275 285
 Asn Asp Ieu Pro Glu Thr Ala Val Ile Gly Leu Leu Trp Thr Cys
 290 300
 Ile Met Asn Ala Val Glu Trp Asn Lys Lys Glu Glu Leu Val Ala
 305 315
 Gln Gln Ala Leu Lys His Leu Lys Gln Tyr Ala Pro Leu Leu Ala
 320 330
 Val Phe Ser Ser Gln Gly Gln Ser Glu Ile Leu Leu Gln Lys
 335 345
 Val Gln Glu Tyr Cys Tyr Asp Asn Ile His Phe Met Lys Ala Phe
 350 360
 Gln Lys Ile Val Val Leu Phe Tyr Lys Ala Asp Val Leu Ser Glu
 365 375
 Glu Ala Ile Leu Lys Trp Tyr Lys Glu Ala His Val Ala Lys Gly
 380 390
 Lys Ser Val Phe Leu Asp Gln Met Lys Lys Phe Val Glu Trp Leu
 395 405
 Gln Asn Ala Glu Glu Glu Ser Glu Ser Glu Gly Glu Glu Asn
 410 415

<210> 7
 <211> 152
 <212> PRT
 <213> Homo sapiens

<220> -
<223> 1605720

<400> 7
 Met Glu Ala Val Leu Asn Glu Leu Val Ser Val Glu Asp Leu Leu
 1 5 10 15
 Lys Phe Glu Lys Lys Phe Gln Ser Glu Lys Ala Ala Gly Ser Val
 20 25 30
 Ser Lys Ser Thr Gln Phe Glu Tyr Ala Trp Cys Leu Val Arg Ser
 35 40 45
 Lys Tyr Asn Asp Asp Ile Arg Lys Gly Ile Val Leu Leu Glu Glu
 50 55 60
 Leu Leu Pro Lys Gly Ser Lys Glu Glu Gln Arg Asp Tyr Val Phe
 65 70 75
 Tyr Leu Ala Val Gly Asn Tyr Arg Leu Lys Glu Tyr Glu Lys Ala
 80 85 90
 Leu Lys Tyr Val Arg Gly Leu Leu Gln Thr Glu Pro Gln Asn Asn
 95 100 105
 Gln Ala Lys Glu Leu Glu Arg Leu Ile Asp Lys Ala Met Lys Lys
 110 115 120
 Asp Gly Leu Val Gly Met Ala Ile Val Gly Gly Met Ala Leu Gly
 125 130 135
 Val Ala Gly Leu Ala Gly Leu Ile Gly Leu Ala Val Ser Lys Ser
 140 145 150
 Lys Phe

<210> 8
 <211> 811
 <212> PRT
 <213> Homo sapiens

<220> -
<223> 2515476CD1

<400> 8
 Met Pro Leu Ser Ser Pro Asn Ala Ala Ala Thr Ala Ser Asp Met
 1 5 10 15
 Asp Lys Asn Ser Gly Ser Asn Ser Ser Ser Ala Ser Ser Gly Ser
 20 25 30
 Ser Lys Gly Gln Gln Pro Pro Arg Ser Ala Ser Ala Gly Pro Ala
 35 40 45
 Gly Glu Ser Lys Pro Lys Ser Asp Gly Lys Asn Ser Ser Gly Ser
 50 55 60
 Lys Arg Tyr Asn Arg Lys Arg Glu Leu Ser Tyr Pro Lys Asn Glu
 65 70 75
 Ser Phe Asn Asn Gln Ser Arg Arg Ser Ser Ser Gln Lys Ser Lys
 80 85 90
 Thr Phe Asn Lys Met Pro Pro Gln Arg Gly Gly Ser Ser Lys
 95 100 105
 Leu Phe Ser Ser Ser Phe Asn Gly Gly Arg Arg Asp Glu Val Ala
 110 115 120
 Glu Ala Gln Arg Ala Glu Phe Ser Pro Ala Gln Phe Ser Gly Pro
 125 130 135
 Lys Lys Ile Asn Leu Asn His Leu Leu Asn Phe Thr Phe Glu Pro
 140 145 150
 Arg Gly Gln Thr Gly His Phe Glu Gly Ser Gly His Gly Ser Trp
 155 160 165
 Gly Lys Arg Asn Lys Trp Gly His Lys Pro Phe Asn Lys Glu Leu
 170 175 180
 Phe Leu Gln Ala Asn Cys Gln Phe Val Val Ser Glu Asp Gln Asp
 185 190 195
 Tyr Thr Ala His Phe Ala Asp Pro Asp Thr Leu Val Asn Trp Asp

200	205	210
Phe Val Glu Gln Val Arg Ile Cys Ser His	Glu Val Pro Ser Cys	
215	220	225
Pro Ile Cys Leu Tyr Pro Pro Thr Ala Ala	Lys Ile Thr Arg Cys	
230	235	240
Gly His Ile Phe Cys Trp Ala Cys Ile Leu	His Tyr Leu Ser Leu	
245	250	255
Ser Glu Lys Thr Trp Ser Lys Cys Pro Ile	Cys Tyr Ser Ser Val	
260	265	270
His Lys Lys Asp Leu Lys Ser Val Val Ala	Thr Glu Ser His Gln	
275	280	285
Tyr Val Val Gly Asp Thr Ile Thr Met Gln	Leu Met Lys Arg Glu	
290	295	300
Lys Gly Val Leu Val Ala Leu Pro Lys Ser	Lys Trp Met Asn Val	
305	310	315
Asp His Pro Ile His Leu Gly Asp Glu Gln	His Ser Gln Tyr Ser	
320	325	330
Lys Leu Leu Leu Ala Ser Lys Glu Gln Val	Leu His Arg Val Val	
335	340	345
Leu Glu Glu Lys Val Aia Leu Glu Gln Gln	Leu Ala Glu Glu Lys	
350	355	360
His Thr Pro Glu Ser Cys Phe Ile Glu Ala	Aia Ile Gln Glu Leu	
365	370	375
Lys Thr Arg Glu Glu Ala Leu Ser Gly Leu	Aia Gly Ser Arg Arg	
380	385	390
Glu Val Thr Gly Val Val Ala Ala Leu Glu	Gln Leu Val Leu Met	
395	400	405
Aia Pro Leu Ala Lys Glu Ser Val Phe Gln	Pro Arg Lys Gly Val	
410	415	420
Leu Glu Tyr Leu Ser Ala Phe Asp Glu Glu	Thr Thr Glu Val Cys	
425	430	435
Ser Leu Asp Thr Pro Ser Arg Pro Leu Ala	Ieu Pro Leu Val Glu	
440	445	450
Glu Glu Glu Ala Val Ser Glu Pro Glu Pro	Glu Gly Leu Pro Glu	
455	460	465
Aia Cys Asp Asp Leu Glu Leu Ala Asp Asp	Asn Leu Lys Glu Gly	
470	475	480
Thr Ile Cys Thr Glu Ser Ser Gln Gln Glu	Pro Ile Thr Lys Ser	
485	490	495
Gly Phe Thr Arg Leu Ser Ser Ser Pro Cys	Tyr Tyr Phe Tyr Gln	
500	505	510
Aia Glu Asp Gly Gln His Met Phe Leu His	Pro Val Asn Val Arg	
515	520	525
Cys Ieu Val Arg Glu Tyr Gly Ser Leu Glu	Arg Ser Pro Glu Lys	
530	535	540
Ile Ser Ala Thr Val Val Glu Ile Aia Gly	Tyr Ser Met Ser Glu	
545	550	555
Asp Val Arg Gln Arg His Arg Tyr Leu Ser	His Leu Pro Leu Thr	
560	565	570
Cys Glu Phe Ser Ile Cys Glu Leu Ala Leu	Gln Pro Pro Val Val	
575	580	585
Ser Lys Glu Thr Leu Glu Met Phe Ser Asp	Asp Ile Glu Lys Arg	
590	595	600
Lys Arg Gln Arg Gln Lys Lys Ala Arg Glu	Glu Arg Arg Arg Glu	
605	610	615
Arg Arg Ile Glu Ile Glu Glu Asn Lys Lys	Gln Gly Lys Tyr Pro	
620	625	630
Glu Val His Ile Pro Leu Glu Asn Leu Gln	Gln Phe Pro Ala Phe	
635	640	645
Asn Ser Tyr Thr Cys Ser Ser Asp Ser Ala	Ieu Gly Pro Thr Ser	
650	655	660
Thr Glu Gly His Gly Ala Leu Ser Ile Ser	Pro Leu Ser Arg Ser	
665	670	675
Pro Gly Ser His Ala Asp Phe Leu Leu Thr	Pro Leu Ser Pro Thr	
680	685	690

Ala Ser Gin Gly Ser Pro Ser Phe Cys Val Gly Ser Leu Glu Glu
 695 700 705
 ASP Ser Pro Phe Pro Ser Phe Ala Gln Met Leu Arg Val Gly Lys
 710 715 720
 Ala Lys Ala Asp Val Trp Pro Lys Thr Ala Pro Lys Lys Asp Glu
 725 730 735
 Asn Ser Leu Val Pro Pro Ala Pro Val Asp Ser Asp Gly Glu Ser
 740 745 750
 Asp Asn Ser Asp Arg Val Pro Val Pro Ser Phe Gln Asn Ser Phe
 755 760 765
 Ser Gln Ala Ile Glu Ala Ala Phe Met Lys Leu Asp Thr Pro Ala
 770 775 780
 Thr Ser Asp Pro Leu Ser Glu Glu Lys Gly Gly Lys Lys Arg Lys
 785 790 795
 Lys Gln Lys Gln Lys Leu Leu Phe Ser Thr Ser Val Val His Thr
 800 805 810
 Lys

<210> 9
 <211> 352
 <212> PRT
 <213> homo sapiens

<220> -
 <223> 2754573

<400> 9
 Met His Val Val Ala Pro Ala Ser Leu Arg Leu Gly Thr Gly Thr
 1 5 10 15
 Asn Leu Pro Pro Ser Pro Thr Cys Leu Thr Lys Leu Ala Leu Pro
 20 25 30
 Pro Ala Ala Gln Pro Ser Leu Leu Ala Met Ser Gln Ser Arg His
 35 40 45
 Arg Ala Glu Ala Pro Pro Leu Glu Arg Glu Asp Ser Gly Thr Phe
 50 55 60
 Ser Leu Gly Lys Met Ile Thr Ala Lys Pro Gly Lys Thr Pro Ile
 65 70 75
 Gln Val Leu His Glu Tyr Gly Met Lys Thr Lys Asn Ile Pro Val
 80 85 90
 Tyr Glu Cys Glu Arg Ser Asp Val Gln Ile His Val Pro Thr Phe
 95 100 105
 Thr Phe Arg Val Thr Val Gly Asp Ile Thr Cys Thr Gly Glu Gly
 110 115 120
 Thr Ser Lys Lys Leu Ala Lys His Arg Ala Ala Glu Ala Ile
 125 130 135
 Asn Ile Leu Lys Ala Asn Ala Ser Ile Cys Phe Ala Val Pro Asp
 140 145 150
 Pro Leu Met Pro Asp Pro Ser Lys Gln Pro Lys Asn Gln Leu Asn
 155 160 165
 Pro Ile Gly Ser Leu Gln Glu Leu Ala Ile His His Gly Trp Arg
 170 175 180
 Leu Pro Glu Tyr Thr Leu Ser Gln Glu Gly Pro Ala His Lys
 185 190 195
 Arg Glu Tyr Thr Ile Cys Arg Leu Glu Ser Phe Met Glu Thr
 200 205 210
 Gly Lys Gly Ala Ser Lys Lys Gln Ala Lys Arg Asn Ala Ala Glu
 215 220 225
 Lys Phe Leu Ala Lys Phe Ser Asn Ile Ser Pro Glu Asn His Ile
 230 235 240
 Ser Leu Thr Asn Val Val Gly His Ser Leu Gly Cys Thr Trp His
 245 250 255
 Ser Leu Arg Asn Ser Pro Gly Glu Lys Ile Asn Leu Leu Lys Arg

WO 99/15658

260	265	270
Ser Leu Leu Ser Ile Pro Asn Thr Asp Tyr	Ile Gln Leu Leu Ser	285
275	280	
Glu Ile Ala Lys Glu Gin Gly Phe Asn Ile	Thr Tyr Leu Asp Ile	300
290	295	
Asp Glu Leu Ser Ala Asn Gly Gln Tyr Gln	Cys Leu Ala Glu Leu	315
305	310	
Ser Thr Ser Pro Ile Thr Val Cys His Gly	Ser Gly Ile Ser Cys	330
320	325	
Gly Asn Ala Gln Ser Asp Ala Ala His Asn	Ala Leu Gln Tyr Leu	345
335	340	
Lys Ile Ile Ala Glu Arg Lys		
350		

<210> 10
 <211> 432
 <212> PRT
 <213> Homo sapiens

<220> -
 <223> 2926777

<400> 15
 Met Ile Ser Ala Ala Gln Leu Leu Asp Glu Leu Met Gly Arg Asp
 1 5 10 15
 Arg Asn Leu Ala Pro Asp Glu Lys Arg Thr Asn Val Arg Trp Asp
 20 25 30
 His Glu Ser Val Cys Lys Tyr Tyr Leu Cys Gly Phe Cys Pro Ala
 35 40 45
 Glu Leu Phe Thr Asn Thr Arg Ser Asp Leu Gly Pro Cys Glu Lys
 50 55 60
 Ile His Asp Glu Asn Leu Arg Lys Gln Tyr Glu Lys Ser Ser Arg
 65 70 75
 Phe Met Lys Val Gly Tyr Glu Arg Asp Phe Leu Arg Tyr Leu Gln
 80 85 90
 Ser Leu Leu Ala Glu Val Glu Arg Arg Ile Arg Arg Gly His Ala
 95 100 105
 Arg Leu Ala Leu Ser Gin Asn Gln Gln Ser Ser Gly Ala Ala Gly
 110 115 120
 Pro Thr Gly Lys Asn Gln Glu Lys Ile Gln Val Leu Thr Asp Lys
 125 130 135
 Ile Asp Val Leu Gln Gln Ile Glu Glu Leu Gly Ser Gln Gly
 140 145 150
 Lys Val Glu Glu Ala Gln Gly Met Met Lys Leu Val Glu Gln Leu
 155 160 165
 Lys Glu Glu Arg Glu Leu Leu Arg Ser Thr Ser Thr Ile Glu
 170 175 180
 Ser Phe Ala Ala Gln Glu Lys Gln Met Glu Val Cys Glu Val Cys
 185 190 195
 Gly Ala Phe Leu Ile Val Gly Asp Ala Gln Ser Arg Val Asp Asp
 200 205 210
 His Leu Met Gly Lys Gln His Met Gly Tyr Ala Lys Ile Lys Ala
 215 220 225
 Thr Val Glu Glu Leu Lys Glu Lys Leu Arg Lys Arg Thr Glu Glu
 230 235 240
 Pro Asp Arg Asp Glu Arg Leu Lys Lys Glu Lys Gln Glu Arg Glu
 245 250 255
 Glu Arg Glu Lys Glu Arg Glu Arg Gln Arg Glu Glu Arg Glu Arg
 260 265 270
 Lys Arg Arg Arg Glu Glu Glu Arg Glu Lys Glu Arg Ala Arg
 275 280 285
 Asp Arg Glu Arg Arg Lys Arg Ser Arg Ser Arg Ser Arg His Ser

290	295	300
Ser Arg Thr Ser Asp Arg Arg Cys Ser Arg	Ser Arg Asp His	Lys
305	310	315
Arg Ser Arg Ser Arg Glu Arg Arg Arg	Thr Arg Ser Arg Asp	Arg
320	325	330
Arg Arg Ser Arg Ser His Asp Arg Ser	Glu Arg Lys His Arg	Ser
335	340	345
Arg Ser Arg Asp Arg Arg Arg Ser Lys	Ser Arg Asp Arg Lys	Ser
350	355	360
Tyr Lys His Arg Ser Lys Ser Arg Asp Arg	Glu Gln Asp Arg	Lys
365	370	375
Ser Lys Glu Lys Glu Lys Arg Gly Ser	Asp Asp Lys Lys Ser	Ser
380	385	390
Val Lys Ser Gly Ser Arg Glu Lys Gln	Ser Glu Asp Thr Asn	Thr
395	400	405
Glu Ser Lys Glu Ser Asp Thr Lys Asn	Glu Val Asn Gly	Thr Ser
410	415	420
Glu Asp Ile Lys Ser Glu Gly Asp Thr	Gln Ser Asn	
425	430	

<210> 11
<211> 1750
<212> DNA
<213> Homo sapiens

<220> -
<223> 009476

<400> 11
ggcgcatggt aactcaggcg ccggggcgac tgccttagct gctggtttc cacgctggtt 60
ttagctcccg gcgtctgcaa aatgaagatt gagggaggta agagcactac gaagacgcag 120
cgcatcgctt cccacagccca cgtgaaaggg ctggggctgg acgaaqacggg cttggcaga 180
caggcggctt caggcgttggt gggccaggag aacgcgcggg aggcatgtgg cgtcatagta 240
gaattaaatcg aaagcaagaa aatggctggg agagctgtct tggggcagg acctccctgga 300
actggcaaga cagctctggc tctggctatt gtcaggagc tgggtatcaa ggtcccttc 360
tgcccaatgg tggggagtqa agtttactca actggagatca aqaagacaga ggtgctgtg 420
gagaacttcc gcaggccat tgggctcgaa ataaaggaga ccaaggaaat ttatgaaggt 480
gaagtcacag agctaactcc gtgtqaqaca gagaatccca tgggaggata tggcaaaacc 540
atataqccatg tgatcatagg actcaaaaca gccaaaggaa cccaaacatgtt gaaactggac 600
cccacgatcc ttgaaatgtt gcagaaaagaa ccaatgttgc ctggagatgtt gatttacatt 660
gaagccaaaca gtggggccgtt gaagaggcgg ggcagggtgtt atacctatgc cacaatcc 720
gacttggaaatg ctgaagatgtt gttcccttgc cccaaagggg atgtgcacaa aaadaaaagaa 780
atcatccaag atgtgaccc tcatqacttg gatgtggcta atgcgcggcc ccagggggga 840
caagatatacc tgcctcatgtt gggccagctt atgaagccaa agaagacaga aatcaacagac 900
aaacttcgag gggagattaa taaggtgtt acaactatac tcgaccaggc cattgtgtg 960
ctgttcccggtt gtgtgatgtt gtcacatgc tggacatgtt gtgccttacc 1020
tacactgcacc ggcggccctgaa gtcctccatgc tcatctttgc atccaaccga 1080
ggcaactgtt tcatcagagg cactgaggac atccatccc ctcacggcat ccctcttgc 1140
cttcggacc gatgtgatgtt aatccggacc atgtgttata ctccacagga aatgaaacag 1200
atcattaaaaa tccgtgccccca gacggaaatca acaacatca gtgaggagcc actgaaccac 1260
ctggggggaga ttggcaccatc gaccacactg agttactca gtcagctgtt gacccggcc 1320
aacttgcattt ctaaaatcaa cgggaaggac agttatgtt gaaatgttgc cgaagagatc 1380
agtgaaactt tctatgtatgc caagtccctcc gcaaaaatcc tggctgacca gcaggataag 1440
tacatgtatgtt gatgtggctt aggttttcgtt ctttttttttgc ttttttttttgc ttttttttttgc 1500
tgggtccaggc ctgtggggcgc ttggccctgg gtttggggctt gccgtccccca ctcaggcgtt 1560
gtctgcaggc ctgtcaggatc agtgtggaaa gttttttttt ttaagtttata gtaactgtt 1620
ctgtgggttgc ttttggaaagaa cccttccatca ctttttttttgc ttttttttttgc ttttttttttgc 1680
ttattttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 1740
aaaaaaaaaaaaa 1750

<210> 12

<211> 691
<212> DNA
<213> *Homo sapiens*

<220> -
<223> 077180

<210> 13
<211> 1594
<212> DNA

<213> *Homo sapiens*

<223> 118160

ccgcggccgc	cgggcggtgt	tgtcgtgtgt	gtttggggcc	cgcgcgggtt	gcgcgcctc	60
cgccttcgcg	cctcttgcgc	ccgaggccct	actgctgccc	ctgtccccct	cgccccggcg	120
ggcgtcgcgg	gccaacatgg	gccaggaaga	ggagctgtgt	aggatcgcca	aaaagctggaa	180
aaagatggtg	gccaggaaaga	acacggaaagg	ggccctgtgc	tttctgaaga	agctgcacag	240
ctggccatgc	tccatccagg	tactacagac	aaccaggatt	ggagggtgtc	ttatgggggt	300
ccgcgaagcag	tgctttagaca	aggagggtgt	gtccttgccc	aaagtcttta	tcaaaaactg	360
aaaggcggtg	ctagactccc	ctggacccccc	aaaaggagaaa	aaaggagagg	aaagagaaaa	420
ggcaaaaggaaag	aageaaaaaaag	ggcttgagtg	tccagactgg	aagccagaag	caggcccttc	480
tccaccaagg	aaaaaaacgag	aagaccccaa	aaccaggaga	gactctgtgg	actccaaatgc	540
tctgtccccc	tccttccaa	aaagaccatc	ggtggaaaga	tcaaaacagca	aaatcaaa	600
agcgaggagac	ccccaaaacac	ctagcgcccc	cttgaccccc	acgtttgcct	cttccatgtg	660
tcttcgtggcc	cccttgtatc	tcacagggga	ctctgtccgg	gacaagtgt	ttggagatgt	720
gtcagcagcc	ctgaaggccg	acgtatgatta	caaggactat	ggagtcaact	gtgacaagat	780
ggcatcagaa	atcgaagatc	atatctacca	agagctcaag	agcacggaca	tgaagtaccg	840
gaaaccgcgtg	cgcagccgca	taagcaacct	caaggacccc	aggaaccccg	gcctgcggcg	900
gaacgtgttc	agtggggcca	tctccgcaagg	gtttatagec	aaagtgcacgg	cagagaaat	960
ggccagtgat	gaactgggg	agttggaggaa	tgcattgacc	caggaggccca	tccgtgtgaca	1020
ccagatggcc	aagactggcc	gcaccacacc	tgacctttc	catgtcagca	aatgcagaagaa	1080
gaagaactgc	accataaacc	aggtgcagac	acgcgtgtc	gatgagccca	tgactacctt	1140
tgtcttatgc	aatgaatgtg	gcaatcgctg	gaagttcgc	tgatgaaaca	gccagccatg	1200
aaacaaggtga	ggaagaagaa	agaggaagcg	ctgaattatc	tgaactggag	aagcaataaa	1260
aaattaaatgt	aaggaaaata	ctgaactctg	tctgtgggg	atggatgtag	ttagggaaag	1320
aaattctttg	caaattaata	atcgttgcatt	agaaaacatt	ggttaatggg	ggagccataat	1380
tggagaatgt	tgcgtgagaat	ttgtatgtat	gaaccccttt	tagaaactgc	agagggctgg	1440
gcacgggtggc	ttaatggctt	aatctgcaaa	ctctgggggg	ctgaggtggg	agaatcgctt	1500
aaccccaagaa	gtttagtgc	agccccaggca	acacagcaag	accccatctc	tataaaaaga	1560
aaaataaaag	aaatgttaga	cgccctcgcccc	acat			1594

<210> 14
<211> 821
<212> DNA
<213> *Homo sapiens*

<220> -
<223> 933353

```

<400> 14
cggggtccggc ctgcgcggg cggggatggc ggccaccgcg ctgtggagg cgggcgtggc 60
gcgggtgtct ttctacccga cgctgtctca caccctgtc cgccggaaagg tgccgggtc 120
ggccacccgg gactggtacc accgcatacg ccccacccgtg ctgtgggcg cgctgcgtt 180
gcggagctt acgcggcagc ttgtacagga cgagaacgtg cgggggtga tcaccatgaa 240
cgaggagttac gagacgaggt tcctgtgca ctttcacag gagtggaaaga gactaggagt 300
tgagcagctg cggctcagca cagtagacat gactggatc cccacccgttgg acaacctcca 360
gaagggagtc caattgtct tcaagtatcca gtcgtggc cagttgtttt acgtgtcattt 420
taaggctggg cgctccagga gtgccactat ggtggcaqca tacctgattc aggtgcacaa 480
atggagttca gagggaggctg taagagccat cgccaaagatc cggtcataca tccacatcag 540
gcctggccag ctggatgttc ttaaagaggat ccacaagcag attactgcac gggcaacaaa 600
ggatggggact ttgtcattt caaagacatg atgtatgggg attagaaaga actcaagaca 660
ctccgtctt atacagaaca aaaagagctt aacaggacca acagggttta agcccaagact 720
ttgtacgtaaaca gaaatgtgcc aataggtat aggttaattt tctttctctgt acttgtttt 780
ttttcttqaa ataacactgt tttgtggctt gaaaaaaaaa a 821

```

<210> 15
<211> 2028
<212> DNA
<213> *Homo sapiens*

```
<220>
<221> unsure
<222> 2, 4, 6, 7, 15, 18, 19, 41, 59, 70, 74, 95, 97, 119, 127,
<221> unsure
<222> 131, 152, 158, 889
<223> a or q or c or t, unknown, or other
```

<220> -
<223> 1568361

<400> 15	gnanannnacc	ctgggggnng	ccattcaccg	accctgccc	nacagccgtc	accctcgant	60
cctggctgan	tcnttcctg	gcagttcccc	ttatnanggt	tacaatatg	gctcccttta	120	
caatgtntct	ntaictaccg	atggttctgt	inacagcnct	ggcactgggg	accctcttta	180	
cggtttacca	ggccgctcc	ttaaacctgt	aggtactcgg	ccccqagtgg	actccatgag	240	
ctctgtggag	gaggatgact	acgacacatt	gaccqacatc	gattccgaca	aqaatgtcat	300	
tcgcaccaag	caatacctct	atgtggctga	cctggcacgg	aaggacaagc	gttgtctgcg	360	
aaaaaaagtac	catgatctact	tttggaaacat	tgcacccatt	gctgtcttct	atgccttcc	420	
tgtgggtcgag	ctgggtatca	cttaccaggac	ggtggtrgaat	gtcacaaggga	atcaggacat	480	
ctgttactac	aacttctct	gccccccacc	acttggcaat	ctcagcgcct	tcaacaacat	540	
cctcagcaac	ctggggtaca	ttctgtggg	gctqcttts	ctgctcatca	tccrigcaacg	600	
ggagatcaac	cacaaccggg	ccctgtgcg	caatgaccc	tgtgccctcg	aatgtggat	660	
ccccaaacac	tttggcttt	tttacgccat	gggcacagcc	ctgatgtatgg	aggggctgct	720	
catgtctgc	tatcatgtgt	cccccaacta	taccaattt	cagtgttgcaca	catcggtcat	780	
gtacatgatc	gcccggactct	gcatgtctaa	gcttcttacag	aaggccgcacc	ccggacatcaa	840	
cgccagcgcc	taatgtgcct	acgcctgcct	ggccatttgc	atcttcttnt	ctgtgtctggg	900	
cgtggcttct	ggcaaaaggga	acacggcggtt	ctggatgc	tttcccatca	ttcacatcat	960	
cgccacccctg	cttctcagca	cgcaagctcta	ttacatgggg	cggtggaaac	tggactcggg	1020	
gatcttccgc	cgcatccctcc	acgtgtctta	cacagactgc	atccggcagt	gcagcggggcc	1080	
gtcttacgtt	gaccgcattgg	tgctgtctgtt	caatggcaac	gtcatcaact	gtgtcgctggc	1140	
tgcctatggg	tttatcatgc	gcccccaatg	tttgcgttcc	tacttgttgg	ccattggcact	1200	
ctgcaacttg	ctttttttact	tcgccttctta	catcatatcg	aagctccggaa	gtgggggagaa	1260	
gatcaagctc	atccccctgc	tctgcatctgt	ttgcaccccc	gtgtgtctggg	gtttcgcgct	1320	
cttcttcttc	ttccaggggac	ttagcacctgt	gcagaaaaacs	cctgcagagt	cgaggggagca	1380	
caaccggggac	tgcattctcc	tcgacttctt	tgacgaccas	gacatctggc	acttccctctc	1440	
ctccatcgcc	atgttcgggt	ccttcctgtgtt	gttgcgtaca	ctggatgcac	acctggatata	1500	
tgtgcagcgg	gacaagatct	atgttcttct	gcaggagctg	ggcccttcgc	ttcacctcaa	1560	
ggggccctgt	gtcttcttctgt	gtcatagacc	ggtcaactgt	tcgtgtctgtg	ggatgaggtc	1620	
ccagacccgc	tcccccagcac	tggatggcag	caggacagcc	aggttctagct	taggcttggc	1680	
ctggggacacg	catggggatgg	catggaaacct	tgcaatgtcc	ctctgcggag	gaggcaggccct	1740	

gctccccctgg aaccccccaga ttttggccaa attgtgtctt tcttctcagt gttggggcct 1800
 tccatgggcc cctgtccctt ggctctccat ttgtccctt gcaagaggaa ggtatggaaagg 1860
 gacacctcc ecatttcatg cttgcattt tgeccgtctt cctcccccaca atgccccagc 1920
 ctgggaccta aggccctttt ttccctccat actcccaactc cagggcctag tctggggcct 1980
 gaatctctgt cctgtatcg ggccccagtt ctctttggc tttccctg 2028

<210> 16
 <211> 1830
 <212> DNA
 <213> Homo sapiens

<220> -
 <223> 1600438

<400> 16
 gtcaatgtgt ctgtccttca ctccctccatt gtctggccgactgtgtctg ctgtgtctgc 60
 tgccgtgtct gctgcacgaa tcgtcgcagc cccagccctt ggcgcgtcgctc gtcacccctt 120
 cggacagaaa ttatgaat aagcatcaga agccatgtctt aacaggccag cggttcaaaa 180
 ctcggaaaag ggtgaaaaa gagaatccg aaccacatgtt cttcaggat acacttgc 240
 aggggtttaa tgaggctgtt gatgacccctt aagctgttgc caaatttctt gactctacag 300
 gctcaagattt agattatgtt cgctatgcag acacacttcc cgtatatccctt gtggctggca 360
 gtatgttgc ccctggagga acgcgcatacg atgtgttgc caagaccaag atgaccaacc 420
 actgtgtgtt ttcagcaat gaagatcatg aaaccatccg aaactatgtt caggtcttca 480
 ataaacttca caggagatataat aagtatttttgg agaaggatgtt tgaagatgaa atgaaaaaaggc 540
 ttcccttctt ccttaaagcc ttttccgaaa cagagccatgc aaaggatggcg atgtgtcg 600
 ggatttgcgtt gggcaatggc accctgcctcc ccacatccctt caccatgtt ttcaccgaca 660
 gcttagtcaa agaaggccattt gcccgcctcat ttgtgttcaat gctttcaaaa gcatggatgg 720
 caaaaaaaga tgccaaacttctt ttttgcgtt ctttggaaaaa agccaacttca gacaaggagc 780
 tgcttgaact ctttccagtt aacagacaga gtgtggatca ttttgcataa tacttcaactg 840
 acgcaggctt taaggagctt tccgacttcc tccgagttca gcaatccctt ggcaccaggaa 900
 aggaatgcga gaaggagctc caggagcttc ttttccatggat atgcccgttcc aaggagggtgg 960
 tgctttatgtt caaaaagaa atgaagagga atgatgttcc agaaacagca gtgattggtc 1020
 ttctgtggac atgtataatgtt aacgtgtgtt aatggaaaca gaaaggagaa cttgttgcag 1080
 agcaggcttca gaaaggatgtt aacgtgtgtt aatggaaaca gaaaggagaa cttgttgcag 1140
 gccagtcaga gctgtatccctt ctccagaagg ttcaggaata ctgctacgc aacatccatt 1200
 tcatgaaaggc ctttcagaag attgtgttgc tttttataa agctgtatgtt ctgagcgaag 1260
 aagcaataact gaaatgtt aaggaaggcac atgtgttcaat gtttttctt gtttttctt 1320
 accagatgaa gaaatgtt aatggatgtt aatggaaaca gaaaggagaa cttgttgcag 1380
 gtgagggaaa ttaatgtgtt caacaaggac aataacttggat ttttgcataa ccacttttttgc 1440
 attggaaatgtt ctgaaaccattt tgagaaggaa aacttggatgtt ctgttttgcg 1500
 aaaaatgtttaggc ttttgcgtt ttttggatgtt gggggaaatgg ttttgcgtt gtttttgcgtt 1560
 taaaatggatgtt ctttgcgtt aatggatgtt aatggatgtt gtttttgcgtt gtttttgcgtt 1620
 gctaaatccaa accatttcaaa caaggagtc aatggatgtt aatggatgtt gtttttgcgtt 1680
 tcctcccttta ttagctgtat ttttgcgtt ctgtgttgc accggcccccac ttttgcgtt gtttttgcgtt 1740
 tacaggccac ttttgcgtt gtttttgcgtt ttttgcgtt gtttttgcgtt gtttttgcgtt 1800
 taaaataat ggttttttaa gaaaaaaa 1830

<210> 17
 <211> 566
 <212> DNA
 <213> Homo sapiens

<220> -
 <223> 1605720

<400> 17
 gttctccggcc cctgcccactg ggccatggag actgtggcac agtagactgtt agtgtggggc 60
 tcgcgggggc agtggccatg gaggccgtgc tgaacgactgtt ggtgtctgtt gaggacctgc 120
 tgaatgttga aaaaatgtt ctttgcgtt aatggatgtt gtttttgcgtt gtttttgcgtt 180
 agtttgcgtt ctttgcgtt aatggatgtt gtttttgcgtt gtttttgcgtt gtttttgcgtt 240
 tcgtgtgtctt ctttgcgtt aatggatgtt gtttttgcgtt gtttttgcgtt gtttttgcgtt 300
 tctacccgtt ctttgcgtt aatggatgtt gtttttgcgtt gtttttgcgtt gtttttgcgtt 360
 gcggttgcgtt gtttttgcgtt gtttttgcgtt gtttttgcgtt gtttttgcgtt gtttttgcgtt 420

acaaggccat gaagaaaat ggactcgtag gcatggccat cgtgggaggc atggccctgg 480
gtgtggccgg gtatggccgga ctcatcgac ttgtgtgtc caagtccaaa ttctgtaaagg 540
qacqcgggag cccacggaga acgctc 566

<210> 18
<211> 3520
<212> DNA
<213> *Homo sapiens*

<220> -
<223> 2515476

<400> 18
 gagaagccaa ggaaggaaac agggaaaaat gtcggcatga aggccgagaa ccgctgccgc 60
 cgccgacccc cgccggccct gaacgcatg agcctggtc cccggcgcgc ccgctccgc 120
 tcgactggc tcgccccgaa ggccccgtt gatgccgtg agctccccca acggccgcgc 180
 caccgcctcc gacatggaca agaacagcg ctccaaacagc tcctccgcct ttccggcga 240
 cagcaaaaggc caacagccgc cccgctccgc ctggggggg ccagccggcg agtctaaacc 300
 caagagcgat ggaagaact ccagtggatc caagcggtt aatcgcaaaac gtgaactttc 360
 ctaccccaaa aatgaaaaggta ttaacaacca gtcccgctgc tccaggatc acaaaagcaa 420
 gacttttaac aagatgcctc ctcaaaagggg cggggcgcg acaaaactct ttactcttc 480
 ttttaatgtt ggaagacgag atgaggatgc agaggtctaa cgggcagagt tttagccctgc 540
 ccgatctctt ggtcttaaga agatcaacctt gaaccactt gttgaatttca cttttaaacc 600
 ccgtggcccg acgggtcaact ttgaaggcgag tggacatgtt agctggggaa agaggaacaa 660
 gtggggacat aagcccttta acaaggaaactt ctttttacag gccaactgccc aatttgtgtt 720
 gtctgaagac caagactaca cagtcattt tgctgtatcc tatacattag ttaactgggg 780
 ctttggaaa caagtgcgc ttgttagccca tgaagtgccca tcttgcggaa tatgcctcta 840
 tccaccaact gcaagccaaaga taacccgttgg tggacacatc ttctgctggg acgtcatcc 900
 gcaactatctt tcactgtgtt aagagacgtt gatggaaatgtt cccatctgtt acagtctgt 960
 gcaataagaag gatctcaaga gtgttgttgc cacagagtca catcagtatg ttgttgtga 1020
 taccattacg atgcagctga tgaagagggg gaaagggttgg ttgttgttgc ttcccaaattc 1080
 caaatggatg aatgttagacc atcccattca tcttaggatg gaacagcaca gcccgtacte 1140
 caagttgttgc ctggcctcta aggagccagg gtcgcacccgg gtagttctgg aggagaaatg 1200
 agcaactatggc cagcagctgg cagagggaaa gcaacactccc gatcgttgc ttattgtggc 1260
 agtattccatggc gagtcataaaatc ctggggaaa gtcgttgc gatggggccgg gaaqcagaag 1320
 ggagggtcaat ggttgtgttgc ctgtctgtt gcaactgtgtt ctgtatggc ccttggcgaa 1380
 ggagtctgtt ttcaacccca ggaagggtgt gctggagttt ctgtctgtt tcgatgttgc 1440
 aaccacggaa gtttgttctc tggacactcc ttttagacccctt ctgtctgtt ccctgttgc 1500
 agaggaggaa gcagtgttgc aaccagagcc tgagggttgc ccagaggccctt gtgtgttgc 1560
 ggagttatca gatgacaatc tttaaaggagg gaccatttgc actgtgttgc gccacggaga 1620
 acccatccatggc aacttgcggatc tccacccgcg cagcgttgc ctgtttactt atctttacca 1680
 agcggaaatg ggcacgcata tggatgttgc cccctgttgc gatctcagca actgtgttgc 1740
 gtacggcgcg ctggagaggaa gccccggagaa gatctcagca actgtgttgc 1800
 ctactccatggc tctcaggatg ttcgcacgcg tccacatgtt ctctcttactc tgccactcac 1860
 ctgtgttgc aactgttgc tttttttttt gcaacccctt gtgtgttgc 1920
 agagatgttgc tcagatgtaca ttggaaagag gaaacgttgc cggccaaatggc aggtctggg 1980
 ggaacggccgc cgagacgcgc ggttggatg agaggaaac gaaaacagg gcaagttacc 2040
 agaagtccatggc attcccttcg agaatcttaca gcaatgttgc gcttcaattt ctatatactt 2100
 ctccctgtat tctgttttttgc tttttttttt gttccaccatggc tttttttttt 2160
 tccctcttgc agaagtccatggc gttccatgtt gttttttttt gttccaccatggc tttttttttt 2220
 tgccagttgc ggcgttccctt catttgcgtt tggggatgttgc gaaagatgttgc tttttttttt 2280
 tcccttttgc cagatgttgc tttttttttt gttttttttt gttttttttt 2340
 tccaaagaaa gatgagaaca gttttttttt tttttttttt gttttttttt 2400
 tgataatttca gaccgttttc ctgtgtttttt gttttttttt gttttttttt 2460
 agcagcttc atgaaacttgg acacacccatggc tttttttttt gttttttttt 2520
 agggaaaatggc agaaaaaaatggc agaaaacaggaa gttttttttt gttttttttt 2580
 caaagtgttgc tttttttttt gttttttttt gttttttttt 2640
 cccccatgtt gttttttttt gttttttttt gttttttttt 2700
 ctgggggggg ggggggttccaaatgttgc tttttttttt gttttttttt 2760
 ttttccatggc tccatgttgc tttttttttt gttttttttt 2820
 caagggtttt gttttttttt gttttttttt 2880
 aacccaaatggc aagatgttgc ccccttttgc tttttttttt 2940
 acacactgtt gttttttttt gttttttttt 3000
 tttttttttt gttttttttt 3060

```

ggggggggaa taaaatggat ttaggacacc cagtttgaat tgcagttttt ttttttctga 3120
cacatggccca ggctgtggtg ccagcttaat ggagtaggct gtccttggca cttgcatgtg 3180
tggaaaggagg gttttgcctc ttcttgagca tggcttgagt tggttaaggaa agctgttaact 3240
cacgaaggccc tgagacctgc taccccttaag atcgcagtttgc ttttcgttgc ctggcttgag 3300
tcataggagg aggagttcttg tacagctgca ggagagcagg ggcattgtaa gccgttagcat 3360
tgccaccatc tcccttcatc cttagacgttttgcattatgc cttggtttga gctgaatttg 3420
atgttgcattc ttttgtgtct taataaaatgtt acctcttaggtt gcatttagaaat ggcgttgc 3480
atagttgcattc taaaatccatc gcacaaggcaaaa 3520

```

<210> 19

<211> 1904

<212> DNA

<213> Hama sapiens

<220>

<221> unsure

<222> 32, 33

<223> a or g or c or t, unknown, or other

<220> -

<223> 2754573

<400> 19

cgggggagtc	ggaggagggtg	ggccgcgtgg	anntccccc	ggggaccgc	gactttggag	60
catgcacetc	gtcgacccaaq	cttcactgg	gttggaaaca	ggaactaatc	tcccrcccat	120
tccaaactgc	ttgacaaagg	tcgtcttcc	tcagccgt	gacgcgtccc	tttcgcct	180
gtccccagac	aggccacgcg	ccgaggcccc	gcccgtggag	cgcgaggaca	gtgggacctt	240
cagtttgggg	aaqatqataa	caqctaagcc	aggggaaaaca	ccgatttcagg	tattacacga	300
atacggcatg	aagaccaaga	acatcccagt	ttatgaatgt	gaaagatctg	atgtgcaat	360
acacgtgccc	actttcacct	tcaagtagaac	cggtgggtac	ataacctgca	cagggtgaagg	420
tacaagtaag	aagctggcga	aacatagagc	tgcagaggtc	gccataaaaca	ttttgaagc	480
caatgcaagt	atttgccttg	caggctcttgc	cccccttaatg	cctgaccctt	ccaaagcaacc	540
aaagaaccag	cttaatcttca	ttgggttcatt	acagggaaat	gttatttcattc	atggctggag	600
acttccctgaa	tataccctt	cccaggaggg	aggacctgtc	cataagagag	aatataactac	660
aatttgcagg	ctagagtcat	ttatggaaac	tggaaaggggg	gcatcaaaaa	agcaagccaa	720
aaggaaatqct	gctgagaaat	ttcttgccaa	atttagtaat	atttctccag	agaaccacat	780
ttcttttaca	aatgttagtag	gacattctt	aggatgtact	tggcattctt	tgaggaaattc	840
tcctggtaa	aagatcaact	taactgaaaag	aaggcctctt	agtatccaa	atacagattt	900
catcccgctg	cttagtggaa	ttgccaaggg	acaagggtt	ataataacat	atttggatat	960
agatgaactg	agcccaatgt	gacaataatca	atgtttgtc	gaactgtcca	ccagccccat	1020
cacagtctgt	catgctccg	gtatctctg	tggcaatgca	caaagtgtat	cagctcacaa	1080
tgctttgcag	tatttaaaga	taatagcaga	aagaaagtaa	atctggagca	actaaaaaaa	1140
tcttcagta	gcacataaaa	agttccccc	tggccccc	ccaaagtaaaa	cttttaccgt	1200
agtgtttatg	tcttgtttct	aaatcttc	atagatttca	tcaacactcc	agattttat	1260
atctccctcat	agtgttttatt	aaatctttt	taatggcttc	aactttgtat	cagtatactg	1320
tatttataaa	ctttgtacca	caagagagag	tgtagcacc	attttacagt	gccccatgcaca	1380
tcagagaaag	aaacttgcatg	tttgggttgc	atgtatggaaat	aaaaatgtca	gcgacagtct	1440
ttcttactgg	tgcttaagct	tttctttgc	caaagctta	taaaggaaat	tcaaaggaag	1500
cccttttagaa	ttagagtctt	gagggacagc	actaacaggc	cttttattaag	tatgtattgt	1560
tgttaaattt	cagggAACAT	gattggctcg	ctgtgtatt	gaattcatgt	acaaaagaaac	1620
tgttacgtat	ggatctgtct	catttttata	aaaagctact	gactgtactg	tcatctctgt	1680
cttgttagcc	atttgtaaata	agattttaat	gttgataatt	ctgttattta	catacatctcta	1740
atttacttg	aaatcttcaaaag	gtggaaaataaa	aaaatgtatgg	cttaagtaaa	atttacaaac	1800
atacatgtaa	tggtttactt	ccttactttt	tcttaaggta	tgcaacctt	tattttctt	1860
tgacataacc	atacacaggt	gaattactag	tttaaaaaagc	attt		1904

<210> 20

<211> 1621

<212> DNA

<213> *Homo sapiens*

<220> -

<223> 2926777

<400> 20
atggggttt ttaaaggaa ggcgtccgcg cggccgcat tttgtcttgc cggctccgt 60
gtgttaggagg gatttcggcc ttagagacggg ccgaggagat tggcgcacgt gtcggccgtg 120
ctttcggtg gccccgtgcct gggctggggaa acatggatgg cccggggacc gaaacccatgc cccggacgag 180
tcggccgcg agttgttggaa tgagttaatggccggggacc gaaacccatgc cccggacgag 240
aagcgcacaa acgtgcgggtggaccacacgt tctgtatcttgcgtgtga aaaaattcat 300
tgtcctgcgg aattgttacaaatatacgt tctgtatcttgcgtgtga aaaaattcat 360
gatgaaaatc tacgaaaaca gtatggaaac agctctcggtt tcatgaaaatgttggctatgag 420
agagatttt tgcgatactt acagagctt cttgcagaag tagaacgttagt gatcagacga 480
ggccatgctc gtttggcattt atctcaaaac cagcgttctt ctggggccgc tggccaaaca 540
ggcaaaaatg aagaaaaat tcaagggttca acagacaaaa ttgtatgtact tctgcaacag 600
attgaagaat tagggctctga aggaaaatgttggatgatgatgaaatttagttt 660
gagcaattaa aagaagagag agaactgttggccacaa cgtcgacaaat tggatgtttt 720
gctgcacaag aaaaacaaat ggaagggttggatgttggccacaaat gggccctttt aatagtagga 780
gatgcccagt cccgggttggatgttggccacaaat gggccctttt aatagtagga 840
attaaagcta ctgttggatgttggccacaaat gggccctttt aatagtagga 900
cgtgtatggc gtctaaaaaa ggagaagcaa gaaagagaag aaagagaaaaa agaacgggag 960
agagaaaaggaa aagaaaagaga aaggaaaaga cgaagggaaag aggaagaaaag agaaaaagaaa 1020
agggctcgta acagagaaaag aagaaaagaga agtcgatccac gaaatgttggccacaaat gggccctttt 1080
acatcagaca gaagatgcac caggtctcggttggccacaaat ggtcacggaaat gggccctttt 1140
aggccggacca gaagttggatgttggccacaaat gggccctttt aatagtagga 1200
cacagatctc gaagttggatgttggccacaaat gggccctttt aatagtagga 1260
cacaggagca aaatgttggatgttggccacaaat gggccctttt aatagtagga 1320
ggatctgttggatgttggccacaaat gggccctttt aatagtagga 1380
acaaaacactt aatcgttggatgttggccacaaat gggccctttt aatagtagga 1440
attaaatctt aaggttggatgttggccacaaat gggccctttt aatagtagga 1500
acagaggact actgttggatgttggccacaaat gggccctttt aatagtagga 1560
cgacatcaa aaaaatgttggatgttggccacaaat gggccctttt aatagtagga 1620
g



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification 6 : C12N 15/12, C07K 14/47, C12N 15/70, 1/21, A61K 38/17, C07K 16/18, C12Q 1/68</p>		<p>A3</p>	<p>(11) International Publication Number: WO 99/15658</p> <p>(43) International Publication Date: 1 April 1999 (01.04.99)</p>
<p>(21) International Application Number: PCT/US98/19839</p> <p>(22) International Filing Date: 22 September 1998 (22.09.98)</p> <p>(30) Priority Data: 08/933,750 23 September 1997 (23.09.97) US</p> <p>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/933,750 (CIP) Filed on 23 September 1997 (23.09.97)</p> <p>(71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive #12, Mountain View, CA 94040 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). SHAH, Purvi [IN/US]; 1608 Queen Charlotte Drive #5, Sunnyvale, CA 94087 (US). AU-YOUNG, Janice [US/US]; 1419 Kains</p>			<p>Avenue, Berkeley, CA 94702 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). GUEGLER, Karl, J. [CH/US]; 1048 Oakland Avenue, Menlo Park, CA 94025 (US).</p> <p>(74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).</p> <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p>
<p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> <p>(88) Date of publication of the international search report: 10 June 1999 (10.06.99)</p>			
<p>(54) Title: HUMAN REGULATORY MOLECULES</p> <p>(57) Abstract</p> <p>The invention provides human regulatory molecules and polynucleotides (collectively designated HRM) which identify and encode them. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention further provides methods for diagnosing, preventing, and treating disorders associated with expression of human regulatory molecules.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

Int'l. National Application No.
PCT/US 98/19839

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/12 C07K14/47 C12N15/70 C12N1/21 A61K38/17
C07K16/18 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data bases consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MASATO KANEMAKI ET AL.: "Molecular cloning of a rat 49-kDa TBP-interacting protein (TIP49) that is highly homologous to the bacterial RuvB" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 235, no. 1, 9 June 1997, pages 64-68, XP002088338 ORLANDO, FL US see abstract see page 65, left-hand column, paragraph 6 - page 68, left-hand column, paragraph 1; figure 1 -----	1-14, 17, 18, 21-24

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

17 December 1998

Date of mailing of the international search report

03.05.99

Name and mailing address of the ISA

European Patent Office, P.O. 5016 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

MONTERO LOPEZ B.

INTERNATIONAL SEARCH REPORT

national application No.

PCT/US 98/ 19839

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

Please see Further Information sheet enclosed.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

Please see Further Information sheet enclosed.
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please see additional sheet.

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Claims 1-24 partially.

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: Partially 1-24

Human regulatory molecule comprising SEQ ID NO:1, polynucleotide comprising SEQ ID NO:11 encoding the polypeptide, polynucleotides hybridizing therewith or complementary thereto; microarray containing a fragment of a polynucleotide of SEQ ID NO:11; vector and host cell comprising the polynucleotides and use thereof to produce the polypeptide; agonists and antagonists of the polypeptides; pharmaceutical composition comprising the human regulatory protein and antibody binding the same; use thereof in stimulating cell proliferation and preventing cancer; use of the polynucleotides an microarray for detecting expression levels of polynucleotides encoding a human regulatory molecule.

2. Claims: Partially 1-24

Human regulatory molecule comprising SEQ ID NO:2, polynucleotide comprising SEQ ID NO:12 encoding the polypeptide, polynucleotides hybridizing therewith or complementary thereto; microarray containing a fragment of a polynucleotide of SEQ ID NO:12; vector and host cell comprising the polynucleotides and use thereof to produce the polypeptide; agonists and antagonists of the polypeptides; pharmaceutical composition comprising the human regulatory protein and antibody binding the same; use thereof in stimulating cell proliferation and preventing cancer; use of the polynucleotides an microarray for detecting expression levels of polynucleotides encoding a human regulatory molecule.

3. Claims: Partially 1-24

Human regulatory molecule comprising SEQ ID NO:3, polynucleotide comprising SEQ ID NO:13 encoding the polypeptide, polynucleotides hybridizing therewith or complementary thereto; microarray containing a fragment of a polynucleotide of SEQ ID NO:13; vector and host cell comprising the polynucleotides and use thereof to produce the polypeptide; agonists and antagonists of the polypeptides; pharmaceutical composition comprising the human regulatory protein and antibody binding the same; use thereof in stimulating cell proliferation and preventing cancer; use of the polynucleotides an microarray for detecting expression levels of polynucleotides encoding a human regulatory molecule.

4. Claims: Partially 1-24

Human regulatory molecule comprising SEQ ID NO:4, polynucleotide comprising SEQ ID NO:14 encoding the

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

polypeptide, polynucleotides hybridizing therewith or complementary thereto; microarray containing a fragment of a polynucleotide of SEQ ID NO:14; vector and host cell comprising the polynucleotides and use thereof to produce the polypeptide; agonists and antagonists of the polypeptides; pharmaceutical composition comprising the human regulatory protein and antibody binding the same; use thereof in stimulating cell proliferation and preventing cancer; use of the polynucleotides an microarray for detecting expression levels of polynucleotides encoding a human regulatory molecule.

5. Claims: Partially 1-24

Human regulatory molecule comprising SEQ ID NO:5, polynucleotide comprising SEQ ID NO:15 encoding the polypeptide, polynucleotides hybridizing therewith or complementary thereto; microarray containing a fragment of a polynucleotide of SEQ ID NO:15; vector and host cell comprising the polynucleotides and use thereof to produce the polypeptide; agonists and antagonists of the polypeptides; pharmaceutical composition comprising the human regulatory protein and antibody binding the same; use thereof in stimulating cell proliferation and preventing cancer; use of the polynucleotides an microarray for detecting expression levels of polynucleotides encoding a human regulatory molecule.

6. Claims: Partially 1-24

Human regulatory molecule comprising SEQ ID NO:6, polynucleotide comprising SEQ ID NO:16 encoding the polypeptide, polynucleotides hybridizing therewith or complementary thereto; microarray containing a fragment of a polynucleotide of SEQ ID NO:16; vector and host cell comprising the polynucleotides and use thereof to produce the polypeptide; agonists and antagonists of the polypeptides; pharmaceutical composition comprising the human regulatory protein and antibody binding the same; use thereof in stimulating cell proliferation and preventing cancer; use of the polynucleotides an microarray for detecting expression levels of polynucleotides encoding a human regulatory molecule.

7. Claims: Partially 1-24

Human regulatory molecule comprising SEQ ID NO:7, polynucleotide comprising SEQ ID NO:17 encoding the polypeptide, polynucleotides hybridizing therewith or complementary thereto; microarray containing a fragment of a polynucleotide of SEQ ID NO:17; vector and host cell comprising the polynucleotides and use thereof to produce

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

the polypeptide; agonists and antagonists of the polypeptide; pharmaceutical composition comprising the human regulatory protein and antibody binding the same; use thereof in stimulating cell proliferation and preventing cancer; use of the polynucleotides an microarray for detecting expression levels of polynucleotides encoding a human regulatory molecule.

8. Claims: Partially 1-24

Human regulatory molecule comprising SEQ ID NO:8, polynucleotide comprising SEQ ID NO:18 encoding the polypeptide, polynucleotides hybridizing therewith or complementary thereto; microarray containing a fragment of a polynucleotide of SEQ ID NO:18; vector and host cell comprising the polynucleotides and use thereof to produce the polypeptide; agonists and antagonists of the polypeptides; pharmaceutical composition comprising the human regulatory protein and antibody binding the same; use thereof in stimulating cell proliferation and preventing cancer; use of the polynucleotides an microarray for detecting expression levels of polynucleotides encoding a human regulatory molecule.

9. Claims: Partially 1-24

Human regulatory molecule comprising SEQ ID NO:9, polynucleotide comprising SEQ ID NO:19 encoding the polypeptide, polynucleotides hybridizing therewith or complementary thereto; microarray containing a fragment of a polynucleotide of SEQ ID NO:19; vector and host cell comprising the polynucleotides and use thereof to produce the polypeptide; agonists and antagonists of the polypeptide; pharmaceutical composition comprising the human regulatory protein and antibody binding the same; use thereof in stimulating cell proliferation and preventing cancer; use of the polynucleotides an microarray for detecting expression levels of polynucleotides encoding a human regulatory molecule.

10. Claims: Partially 1-24

Human regulatory molecule comprising SEQ ID NO:10, polynucleotide comprising SEQ ID NO:20 encoding the polypeptide, polynucleotides hybridizing therewith or complementary thereto; microarray containing a fragment of a polynucleotide of SEQ ID NO:20; vector and host cell comprising the polynucleotides and use thereof to produce the polypeptide; agonists and antagonists of the polypeptide; pharmaceutical composition comprising the human regulatory protein and antibody binding the same; use thereof in stimulating cell proliferation and preventing

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

cancer; use of the polynucleotides an microarray for detecting expression levels of polynucleotides encoding a human regulatory molecule.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 206

Although claim 17, as far as concerning an in vivo method, and claim 18 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Further defect(s) under Article 17(2)(a):

Claims Nos.: 15, 16, 19, 20

Claims 15, 16, 19 and 20, referring to agonists and antagonists have not been searched due to the lack of technical description therefore.